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Abstract: Background 
The triplet FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and 
irinotecan) plus bevacizumab showed improved outcomes of patients with 
metastatic colorectal cancer, when compared to FOLFIRI (fluorouracil, L-
leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit 
of the upfront exposure to the three cytotoxics when compared with a pre-
planned sequential strategy of doublets was not clear, as well as the 
feasibility and efficacy of therapies after progression. To this purpose, 
we aimed at comparing a pre-planned strategy of upfront FOLFOXIRI 
followed by the reintroduction of the same regimen after disease 
progression to a sequence of mFOLFOX6 (fluorouracil, L-leucovorin, and 
oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab.  
Methods 
TRIBE2 was an open-label, prospective, phase 3 randomised study of 
patients (aged 18-70 years with Eastern Cooperative Oncology Group [ECOG] 
performance status of 2 or less and aged 71-75 years with an ECOG 
performance status of 0), with unresectable, previously untreated 
metastatic colorectal cancer, who were recruited from 58 Italian Oncology 
Units. Patients were stratified according to center, ECOG performance 
status, primary tumour location and previous adjuvant chemotherapy, and 
randomly assigned (1:1) via a web-based procedure to two different 
strategies: first-line mFOLFOX6 plus bevacizumab followed by FOLFIRI plus 
bevacizumab after disease progression (control group) or FOLFOXIRI plus 
bevacizumab followed by the reintroduction of the same regimen after 
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3478102 
disease progression (experimental group). Combination treatments were 
administered up to 8 cycles followed by fluorouracil/L-leucovorin plus 
bevacizumab maintenance until disease progression, unacceptable adverse 
events, or consent withdrawal. Both patients and investigators were aware 
of treatment assignment. The primary endpoint was progression-free 
survival 2, defined as the time from randomization to disease progression 
on any treatment given after first disease progression or death, analysed 
by intention to treat. Safety was assessed in the population of patients 
who received at least one dose of their assigned treatment. The study 
recruitment was completed, and follow-up of participants is still 
ongoing. The trial is registered at Clinicaltrials.gov: NCT02339116. 
Findings 
Between February 26, 2015, and May 15, 2017, 679 patients were randomly 
assigned and received treatment (340 in the control group and 339 in the 
experimental group). 81% of enrolled patients had a right-sided and/or 
RAS or BRAF mutated tumour. At data cut-off (July 30, 2019) the median 
follow-up was 35·9 months (IQR 30·1-41·4). Median progression-free 
survival 2 was 19·2 months (95% CI 17·3-21·4) in the experimental group 
and 16·4 months (95% CI 15·1-17·5) in the control group (hazard ratio 
[HR] 0·74, 95% CI 0·63-0·88; p<0·001). Median 1st progression-free 
survival was 12·0 months (95% CI 11·1-12·9) with FOLFOXIRI plus 
bevacizumab and 9·8 months (95% CI 9·0-10·5) with mFOLFOX6 plus 
bevacizumab (HR 0·74, 95% CI 0·63-0·86, p<0·001). Higher incidences of 
grade 3 or 4 diarrhoea (17% vs 5%, p<0·001), neutropenia (50% vs 21%, 
p<0·001) and febrile neutropenia (7% vs 3%, p=0·045) were reported in the 
experimental group. Out of 570 patients alive at the time of disease 
progression, 82% and 88% received a treatment after progression in the 
experimental and in the control group, respectively. Median 2nd 
progression-free survival was 6·2 months (95% CI 5·6-6·6) in the 
experimental group and 5·6 months (95% CI 4·9-6·4) in the control group, 
(HR 0·87, 95% CI 0·73-1·04; p=0·116). Median overall survival was 27·4 
months (95% CI 23·7-30·0) in the experimental group and 22·5 months (95% 
CI 20·7-24·8) in the control group (HR 0·82, 95% CI 0·68-0·98; p=0·032). 
Interpretation 
Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the 
same regimen in case of disease progression is the best therapeutic 
strategy for patients with metastatic colorectal cancer selected 
according to the study criteria and particularly for those with right-
sided and/or a RAS or BRAF mutated tumours.  
Funding 
Supported by the GONO and the ARCO Foundations. A research grant was 
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The triplet FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and irinotecan) plus bevacizumab 
showed improved outcomes of patients with metastatic colorectal cancer, when compared to 
FOLFIRI (fluorouracil, L-leucovorin, and irinotecan) plus bevacizumab. However, the actual 
benefit of the upfront exposure to the three cytotoxics when compared with a pre-planned 
sequential strategy of doublets was not clear, as well as the feasibility and efficacy of 
therapies after progression. To this purpose, we aimed at comparing a pre-planned strategy of 
upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease 
progression to a sequence of mFOLFOX6 (fluorouracil, L-leucovorin, and oxaliplatin) and 
FOLFIRI doublets, in combination with bevacizumab.  
Methods 
TRIBE2 was an open-label, prospective, phase 3 randomised study of patients (aged 18–70 
years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and 
aged 71–75 years with an ECOG performance status of 0), with unresectable, previously 
untreated metastatic colorectal cancer, who were recruited from 58 Italian Oncology Units. 
Patients were stratified according to center, ECOG performance status, primary tumour 
location and previous adjuvant chemotherapy, and randomly assigned (1:1) via a web-based 
procedure to two different strategies: first-line mFOLFOX6 plus bevacizumab followed by 
FOLFIRI plus bevacizumab after disease progression (control group) or FOLFOXIRI plus 
bevacizumab followed by the reintroduction of the same regimen after disease progression 
(experimental group). Combination treatments were administered up to 8 cycles followed by 
fluorouracil/L-leucovorin plus bevacizumab maintenance until disease progression, 
unacceptable adverse events, or consent withdrawal. Both patients and investigators were 




aware of treatment assignment. The primary endpoint was progression-free survival 2, 
defined as the time from randomization to disease progression on any treatment given after 
first disease progression or death, analysed by intention to treat. Safety was assessed in the 
population of patients who received at least one dose of their assigned treatment. The study 
recruitment was completed, and follow-up of participants is still ongoing. The trial is 
registered at Clinicaltrials.gov: NCT02339116. 
Findings 
Between February 26, 2015, and May 15, 2017, 679 patients were randomly assigned and 
received treatment (340 in the control group and 339 in the experimental group). 81% of 
enrolled patients had a right-sided and/or RAS or BRAF mutated tumour. At data cut-off (July 
30, 2019) the median follow-up was 35·9 months (IQR 30·1-41·4). Median progression-free 
survival 2 was 19·2 months (95% CI 17·3-21·4) in the experimental group and 16·4 months 
(95% CI 15·1-17·5) in the control group (hazard ratio [HR] 0·74, 95% CI 0·63-0·88; p<0·001). 
Median 1st progression-free survival was 12·0 months (95% CI 11·1-12·9) with FOLFOXIRI plus 
bevacizumab and 9·8 months (95% CI 9·0-10·5) with mFOLFOX6 plus bevacizumab (HR 0·74, 
95% CI 0·63-0·86, p<0·001). Higher incidences of grade 3 or 4 diarrhoea (17% vs 5%, p<0·001), 
neutropenia (50% vs 21%, p<0·001) and febrile neutropenia (7% vs 3%, p=0·045) were 
reported in the experimental group. Out of 570 patients alive at the time of disease 
progression, 82% and 88% received a treatment after progression in the experimental and in 
the control group, respectively. Median 2nd progression-free survival was 6·2 months (95% CI 
5·6-6·6) in the experimental group and 5·6 months (95% CI 4·9-6·4) in the control group, (HR 
0·87, 95% CI 0·73-1·04; p=0·116). Median overall survival was 27·4 months (95% CI 23·7–30·0) 
in the experimental group and 22·5 months (95% CI 20·7–24·8) in the control group (HR 0·82, 
95% CI 0·68–0·98; p=0·032). 





Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen in 
case of disease progression is the best therapeutic strategy for patients with metastatic 
colorectal cancer selected according to the study criteria and particularly for those with right-
sided and/or a RAS or BRAF mutated tumours.  
Funding 
Supported by the GONO and the ARCO Foundations. A research grant was provided by F. 
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Several options are currently available for the upfront treatment of metastatic colorectal 
cancer patients. Based on the results of the phase III TRIBE study1,2 and of other phase II 
randomized trials conducted worldwide,3-6 the combination of the three-drugs regimen 
FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and irinotecan) with the antiangiogenic 
bevacizumab is now regarded as a valuable first-line option by major guidelines.7,8  
In fact, the previous TRIBE study by GONO demonstrated significantly better progression-free 
survival (hazard ratio [HR] for progression: 0·77 (95% CI: 0·65-0·93); p=0·003), primary 
endpoint of the study, response rate (odds ratio [OR] for response: 1·59 [95% CI: 1·10-2·28]; 
p=0·006) and overall survival (HR for death: 0·80 (95% CI: 0·65-0·98); p=0·030) with the triplet 
FOLFOXIRI plus bevacizumab when compared with the doublet FOLFIRI (fluorouracil, L-
leucovorin, irinotecan) plus bevacizumab, at the price of an increased incidence of specific 
grade 3 and 4 adverse events (diarrhoea, stomatitis, neutropenia).1,2 
However, since in the TRIBE study treatments after progression were left at investigators’ 
choice and collected as post-study treatments, the efficacy of the triplet when compared with 
the exposure to the same agents in a sequential strategy of less toxic doublets was not 
demonstrated. Furthermore, in spite of the significant benefit achieved in terms of overall 
survival with the intensified chemotherapy backbone, some concerns raised with regard to 
the feasibility and efficacy of treatments after progression following the upfront exposure to 
the three cytotoxics.  
In the last years the role of the inhibition of angiogenesis as a therapeutic strategy in 
metastatic colorectal cancer was strengthened by important achievements in the field of 
maintenance and treatments after progression: following a 4-6 months first-line treatment 
with a combination chemotherapy regimen plus bevacizumab, maintenance with a 




fluoropyrimidine plus bevacizumab until disease progression is recommended,9-12 and the 
continuation of angiogenesis inhibition also beyond disease progression is a valuable option 
supported by evidence from phase III trials.13,14 
From these considerations, the TRIBE2 study was conceived in order to verify whether the 
upfront exposure to the three cytotoxics in the FOLFOXIRI regimen was superior to a pre-
planned sequence of doublets (first-line mFOLFOX6 [fluorouracil, L-leucovorin, oxaliplatin], 
followed by FOLFIRI after disease progression), in the frame of a sustained inhibition of 
angiogenesis with bevacizumab in both groups. 
 
Methods 
Study design and participants 
TRIBE2 (First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus 
bevacizumab at progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus 
bevacizumab at progression in first- and second-line treatment of unresectable metastatic 
colorectal cancer) was a prospective, open-label, multicentre, randomized phase III study that 
included patients with metastatic colorectal cancer recruited from 58 Italian Oncology Units. 
Main inclusion criteria were the following: histologically confirmed colorectal 
adenocarcinoma; age between 18 and 75 years; Eastern Cooperative Oncology Group 
performance status 0–2 if age ≤70 years, or 0 if age 71–75 years; unresectable and 
measurable metastatic disease according to Response Evaluation Criteria In Solid Tumours 
(RECIST) version 1.1;15 adequate bone marrow, hepatic and renal function (neutrophils ≥1·5 × 
10⁹ cells per L, platelets ≥100 × 10⁹ cells per L, and haemoglobin ≥90 g/L; serum bilirubin ≤1·5 
times the upper limit of normal [ULN]; alanine aminotransferase and aspartate 
aminotransferase ≤2·5 × ULN or ≤5 × ULN in the presence of liver metastases; alkaline 




phosphatase ≤2·5 × ULN or ≤5 × ULN in the presence of liver metastases; serum creatinine 
≤1·5 × ULN or creatinine clearance >50 mL/min). Main exclusion criteria were: previous 
palliative chemotherapy or biologic therapy for metastatic disease; adjuvant treatment with 
oxaliplatin; adjuvant treatment with fluoropyrimidine monotherapy completed less than 6 
months before relapse; peripheral neuropathy of grade 2 or higher according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.16 
The study was conducted in accordance with the Declaration of Helsinki and adhered to Good 
Clinical Practice guidelines. Approval for the protocol was obtained from local ethics 
committees of participating sites. All patients provided written informed consent to study 
procedures before enrolment. 
 
Randomisation and masking 
Patients were randomly assigned in a 1:1 ratio to receive either first-line mFOLFOX6 plus 
bevacizumab followed by FOLFIRI plus bevacizumab after disease progression (control group) 
or first-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus 
bevacizumab after disease progression (experimental group). All combination treatments 
were administrated up to 8 cycles followed by fluorouracil/L-leucovorin plus bevacizumab 
maintenance until disease progression, unacceptable adverse events, or consent withdrawal. 
Eligible patients were randomized using a centralized web-based system and stratified 
according to centre, ECOG performance status (0 versus 1–2), primary tumour location (right-
sided versus left-sided or rectum) and previous exposure to an adjuvant treatment (yes versus 
no). The random allocation sequence was generated at the Clinical Trials Coordinating Center, 
Istituto Toscano Tumori (Florence, Italy). Treatment allocation was not masked. 
 




Study treatments and procedures 
Patients received first-line induction with mFOLFOX6 plus bevacizumab (control group), 
consisting of an intravenous infusion of 5 mg/kg of bevacizumab over 30 min, followed by a 85 
mg/m² intravenous infusion of oxaliplatin given concurrently with L-leucovorin at a dose of 
200 mg/m² over 120 min, followed by a 400 mg/m² intravenous bolus of fluorouracil, and a 
2400 mg/m² continuous infusion of fluorouracil for 48 hours, starting on day 1; or FOLFOXIRI 
plus bevacizumab (experimental group), consisting of an intravenous infusion of 5 mg/kg of 
bevacizumab over 30 min, followed by a 165 mg/m² intravenous infusion of irinotecan over 60 
min, followed by an 85 mg/m² intravenous infusion of oxaliplatin given concurrently with L-
leucovorin at a dose of 200 mg/m² for 120 min, followed by a 3200 mg/m² continuous 
infusion of fluorouracil for 48 h, starting on day 1. Treatment cycles were repeated every 14 
days for up to 8 cycles. 
The use of granulocyte colony-stimulating factor was not recommended as primary 
prophylaxis.  
In the case of pre-specified adverse events, treatment modifications were allowed according 
to study protocol. 
Thereafter, maintenance treatment with fluorouracil/L-leucovorin and bevacizumab was 
planned in both groups at same dose used at the last cycle of the induction treatment, every 
14 days, until progressive disease, patient's refusal, unacceptable adverse events or consent 
withdrawal.  
At the first evidence of disease progression, patients enrolled in the control group received 
FOLFIRI plus bevacizumab (5 mg/kg intravenous infusion of bevacizumab for 30 minutes, 
followed by 180 mg/m² intravenous infusion of irinotecan for 120 min given concomitantly 
with a 200 mg/m² intravenous infusion of L-leucovorin, followed by a 400 mg/m² intravenous 




bolus of fluorouracil, and a 2400 mg/m² continuous infusion of fluorouracil for 48 hours, 
starting on day 1), repeated every 14 days for a maximum of 8 cycles, then followed by 
fluorouracil/L-leucovorin and bevacizumab maintenance. Patients enrolled in the 
experimental group received the re-induction of FOLFOXIRI plus bevacizumab (according to 
the above described schedule) up to 8 cycles, followed by fluorouracil/L-leucovorin and 
bevacizumab as maintenance. If disease progression occurred during the first-line induction 
with FOLFOXIRI plus bevacizumab, a second-line treatment at investigator’ s choice was 
allowed.  
In the case of surgical radical resection of residual metastases, post-operative therapy with 
the same pre-operative regimen was planned up to an overall duration of 6 months (12 
cycles), then followed by fluorouracil/L-leucovorin with bevacizumab up to 6 months after 
resection. 
The assessment of response and progression was based on investigator-reported 
measurements, subsequently confirmed by a central review, and was performed according to 
RECIST 1.1 criteria with CT scans repeated every 8 weeks. 15 
At the start of every cycle, the patients’ medical history, ECOG performance status, results of 
physical examination, and adverse events were recorded and graded according to the NCI-
CTCAE version 4.0.16 
 
RAS and BRAF status and microsatellite instability analyses 
Data about RAS (codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS) and BRAF (V600E 
mutation) mutational status were collected based on the local assessment. Microsatellite 
instability was centrally analysed by means of immunohistochemistry as previously 
reported.17-19  






To properly assess the efficacy of the whole first- and second-line strategy, the primary 
endpoint was progression-free survival 2, defined as the time from randomization to disease 
progression, according to RECIST version 1.1,15 on any treatment given after first disease 
progression, or death from any cause. For patients who did not receive any treatment within 3 
months after first disease progression, progression-free survival 2 was equal to 1st 
progression-free survival, defined as the time from randomization to the first evidence of 
disease progression, or death from any cause. Secondary endpoints included 1st progression-
free survival, 2nd progression-free survival, defined as the time between the first and the 
second evidence of disease progression or death from any cause, safety, response rate, radical 
resection rate of metastases and overall survival. 
 
Statistical analyses 
To detect a hazard ratio (HR) for progression-free survival 2 of 0·77 (corresponding to an 
increase in the progression-free survival 2 rate at 15 months from 50% to 60%) in favour of 
the experimental group with an overall two-sided alpha error of 5% and an estimated power 
of 80%, we planned to enrol 654 patients in order to observe 466 events of progression-free 
survival 2 or death from any cause. 
An interim analysis was planned to assess the superiority of the experimental group versus 
the control group for the primary endpoint when 2/3 of the expected progression-free 
survival 2 events had occurred (303 out of 466 events). According to the O’Brien Fleming 
spending rule, two-sided alpha levels of significance were set at 0·0131 and 0·0455 for the 
interim and final analysis, respectively. 




All efficacy analyses were performed on an intention-to-treat basis. Safety, including summary 
of adverse events, was assessed in all enrolled patients who received at least one dose of 
study treatment (safety population). 2nd progression-free survival was assessed also in the per 
protocol population, including patients that received the treatment after progression planned 
according to the random assignment. The rate of adverse events was evaluated in the safety 
population, including patients who received at least one cycle of the study treatment. The 
median period of follow-up was calculated for the entire study cohort according to the 
reverse Kaplan-Meier method. Distributions of time-to-event variables for progression-free 
survival 2, 1st and 2nd progression-free survival, and overall survival were estimated with the 
use of the Kaplan-Meier product-limit method. Cox proportional-hazards modelling was also 
performed as supportive analyses. Subgroup analyses of progression-free survival 2 and 1st 
progression-free survival were performed by means of an interaction test to determine the 
consistency of the treatment effect according to key baseline characteristics. The objective 
response rate, the resection rate for metastases, and the rate of adverse events in the two 
groups were compared with the use of the chi-square test for heterogeneity or with Fisher’s 
exact test when appropriate. All statistical tests were two-sided, and p values of 0·05 or less 
were deemed significant. No adjustments for multiple comparisons were performed.  
Statistical analyses were done using SAS version 9.2.  
The trial is registered with ClinicalTrials.gov, number NCT02339116. 
 
Role of funding source 
The Italian GONO Foundation sponsored the trial and GONO investigators were responsible 
for study design, data collection, data analysis, and data interpretation. The writing of the 
report and the decision to submit for publication was the responsibility of the GONO 




Foundation. The no-profit ARCO Foundation supported molecular analyses, but had no role in 
study design, data collection, data analysis, data interpretation, or writing of the report. F. 
Hoffman-La Roche partially supported the trial with a research grant and providing 
bevacizumab for the whole study treatment of the experimental group and for the treatment 
beyond progression of the control group, but had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author had full 




From February 26th, 2015 to May 15th, 2017, 679 patients with metastatic colorectal cancer 
were randomly assigned to the control (n=340) or the experimental group (n=339) (figure 1). 
Six hundred and seventy-two patients (336 per group) received at least one dose of study 
treatment and were included in the safety population. The cut-off date for the present 
analysis was July 30th, 2019. 
Patients’ demographic, clinical and molecular baseline characteristics were well balanced in 
the two groups (table 1). The median (interquartile range [IQR]) age of the study population 
was 61 (53-67) years and most patients (86%) had an ECOG Performance Status of 0. The 38% 
of patients had a right-sided primary tumour, 59% had multiple sites of metastases and 30% 
had liver-limited disease. RAS and BRAF mutations were found in the 64% and 10% of cases, 
respectively, and the 5% of patients had microsatellite instable (MSI-high) tumours. Overall, 
the 81% of enrolled patients had a right-sided and/or a RAS or BRAF mutated tumour. 
At a median follow-up of 35·9 months (IQR 30·1-41·4), 546 (80%) events of progression-free 
survival 2 [286 (84%) in the control group and 260 (77%) in the experimental group] were 




observed. Median progression-free survival 2 was 19·2 months (95% CI 17·3–21·4) in the 
experimental group and 16·4 months (95% CI 15·1–17·5) in the control group (HR 0·74, 95% CI 
0·63–0·88; p<0·001; figure 2A). Treatment effect was consistent across all analysed clinical 
and molecular subgroups (figure 2B). 
First-line disease progression occurred in 605 (89%) patients: 310 in the control group and 295 
in the experimental group. Median 1st progression-free survival was 12·0 months (95% CI 
11·1-12·9) in the experimental group receiving FOLFOXIRI plus bevacizumab, and 9·8 months 
(95% CI 9·0-10·5) in the control group receiving mFOLFOX6 plus bevacizumab (HR 0·74, 95% CI 
0·63-0·86; p<0·001; figure 3A). Treatment effect was consistent across all analysed clinical and 
molecular subgroups (figure 3B). The response rate according to RECIST 1.1 was 62% (95% CI 
57-67) in the experimental group as compared with 50% (95% CI 45-56) in the control group 
(odds ratio 1·61, 95% CI 1·19–2·18; p=0·002). The rate of R0 resection of metastases (i.e., no 
macroscopic or microscopic residual tumour) was 17% in the experimental group and 12% in 
the control group (odds ratio 1·55, 95% CI 1·00-2·39; p=0·047). The incidence of grade 3 or 4 
neutropenia, febrile neutropenia and diarrhoea was significantly higher in the experimental 
than in the control group (table 2). 
Out of 570 patients still alive at the time of first disease progression (296 in the control group 
and 274 in the experimental group), 259 (88%) in the control group and 224 (82%) in the 
experimental group received a further treatment (figure 1; table S1, appendix). The 2nd 
progression-free survival analysis was based on 511 events (90%) – 272 (92%) in the control 
group and 239 (87%) in the experimental group. Median 2nd progression-free survival was 6·2 
months (95% CI 5·6-6·6) in the experimental group and 5·6 months (95% CI 4·9–6·4) in the 
control group (HR 0·87, 95% CI 0·73–1·04; p=0·116; figure 4A).  




Two-hundred and one patients (78%) in the control group and 132 (59%) in the experimental 
group received the treatment after progression planned according to the random assignment 
(FOLFIRI plus bevacizumab and FOLFOXIRI plus bevacizumab, respectively) and were included 
in the per protocol population (figure 1; table S1, appendix).  
In the per protocol population, the 2nd progression-free survival was based on 186 (93%) 
events in the control group and 115 (87%) in the experimental group. Median 2nd progression-
free survival was 6·5 months (95% CI 6·2–7·5) in the experimental group and 5·8 months (95% 
CI 4·9–6·5) in the control group (HR 0·79, 95% CI 0·63–1·00; p=0·049; figure 4B).  
No significant differences in the incidence of grade 3 or 4 adverse events between FOLFIRI 
plus bevacizumab and FOLFOXIRI plus bevacizumab, given after disease progression, were 
observed, with the only exception of neurotoxicity, whose incidence was significantly higher 
in the experimental than in the control group (table 2). 
The overall survival analysis was based on 459 events (68%) – 241 (71%) in the control group 
and 218 (64%) in the experimental group. Median overall survival was 27·4 months (95% CI 
23·7-30·0) in the experimental group and 22·5 months (95% CI 20·7-24·8) in the control group 
(HR 0·82, 95% CI 0·68-0·98; p=0·032; figure 5). 
 
Discussion 
Our findings demonstrate the superiority of the upfront exposure to FOLFOXIRI plus 
bevacizumab followed by the re-induction with the same agents when compared with a pre-
planned sequential strategy of administration of the three cytotoxics across two subsequent 
lines of therapy (mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab after 
disease progression) in the treatment of patients with metastatic colorectal cancer. Of note, 
the percentage of patients enrolled in the control group and actually exposed to the three 




cytotoxics was as high as 88%, thus further strengthening the clinical significance of the 
advantage reported by the experimental group.  
We provide a meaningful demonstration of the efficacy of FOLFOXIRI plus bevacizumab 
administered up to 8 cycles as first-line option for metastatic colorectal cancer patients, by 
corroborating results previously achieved in the TRIBE trial, where the treatment was planned 
up to 12 cycles.1,2 Indeed, FOLFOXIRI plus bevacizumab was associated with statistically 
significant and clinically relevant improvements in terms of response rate, progression-free 
and overall survival in a population with initial poor prognostic features, thus showing the 
impact of the first-line regimen on the therapeutic route of patients with metastatic colorectal 
cancer, and particularly the high magnitude of the effect of the upfront intensified treatment 
on patients’ long-term outcome. In fact, the 89% of patients included in the TRIBE2 study 
presented with synchronous metastases, the 38% had a right-sided primary tumour, the 59% 
had more than one metastatic site, and the 64% and 10% bore a RAS or BRAF mutated 
tumour, respectively. These poor prognostic features may explain the shorter duration of 
overall survival reported in both groups, when compared with results in the RAS wild-type 
population of other recent randomized trials.20-24 
In terms of safety, the toxicity profiles of study regimens were consistent with the known 
adverse events of the individual drugs, and highly coherent with results from previous studies 
investigating the triplet plus bevacizumab.1,3-6,25-29 The TRIBE2 study was conducted in 58 
Italian sites, highlighting the large scale feasibility of the experimental strategy. 
We also showed that treatments after progression to first-line FOLFOXIRI plus bevacizumab, 
then followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab, were feasible 
in the 82% of patients, and their efficacy was not affected by the upfront exposure to the 
three cytotoxics, as demonstrated by the absence of difference in terms of 2nd progression-




free survival between the two study groups. FOLFOXIRI plus bevacizumab was reintroduced 
after disease progression in the 59% of patients in the experimental group, and a per protocol 
analysis reported a significant advantage in terms of 2nd progression-free survival in these 
patients when compared with those who received FOLFIRI plus bevacizumab after progression 
to first-line mFOLFOX6 plus bevacizumab, with no increase in grade 3 or 4 adverse events 
except for an expected higher incidence of neuropathy. The relatively good tolerability is 
probably explained by a careful clinical selection of those patients able to receive FOLFOXIRI 
plus bevacizumab after progression, made by treating physicians on the basis of their previous 
tolerance to this regimen and of the health status of patients. 
With regard to treatments after progression, a potential limitation of our study is the choice 
to switch to FOLFIRI after first-line mFOLFOX6 instead of re-introducing an oxaliplatin-based 
regimen. Even if this strategy was previously evaluated in clinical trials,30,31 our choice was 
driven by the objective of exposing the highest percentage of patients to the three cytotoxics 
also in the control group. Moreover, by a pragmatic point of view, the switch to the alternate 
doublet is the most common approach in the daily clinical practice. 
As shown by the subgroup analyses, no interaction was observed between treatment effect 
and RAS and BRAF mutational status, as in the previous TRIBE study. Nonetheless, based on 
the high magnitude of benefit reported in the small subgroup of patients with BRAF mutated 
tumours in the previous TRIBE,1,2 FOLFOXIRI plus bevacizumab was identified as a preferable 
option in this subgroup.  The evidence of no increased benefit from the intensified approach 
reported here may be explained by the molecular and clinical heterogeneity of BRAF mutated 
tumours, and the different comparator group (oxaliplatin- instead of irinotecan-based 
doublet).  




Based on previous findings of the TRIBE study, a higher benefit from the experimental 
treatment could be expected among patients with a BRAF mutated tumour. However, also in 
the TRIBE study no significant interaction effect between treatment group and RAS or BRAF 
mutational status was described, thus dictating a cautious interpretation of results achieved in 
small subgroups.  
In order to properly translate our study in the current landscape of the first-line treatment of 
metastatic colorectal cancer, it should be acknowledged that the vast majority (81%) of 
enrolled patients had a right-sided and/or a RAS or BRAF mutated tumour, while only a 
minority (16%) of them had a left-sided and RAS and BRAF wild-type tumour. This might be 
explained by the increased use of chemotherapy plus an anti-Epidermal Growth Factor 
Receptor (EGFR) monoclonal antibody as first-line treatment of patients with RAS and BRAF 
wild-type tumours during the accrual of the TRIBE2 study. As a consequence, the optimal 
candidates to first-line doublets plus anti-EGFR are under-represented in the present study 
and the combination of an anti-EGFR with chemotherapy remains a preferred option for these 
patients. On the other side, a relevant magnitude of benefit was reported among patients 
with a right-sided and/or a RAS or BRAF mutated tumour, thus making upfront FOLFOXIRI plus 
bevacizumab the best first-line option for patients in this subgroup. 
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Panel: Research in context 
Evidence before study 
A previous phase 3 trial (TRIBE study) by the Italian GONO Foundation proved the superiority 
of the first-line triplet regimen FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and 
irinotecan) over the doublet FOLFIRI (fluorouracil, L-leucovorin, and irinotecan) when 
bevacizumab was added to both regimens in patients with unresectable metastatic colorectal 
cancer. Based on these results, FOLFOXIRI plus bevacizumab is supported by all major clinical 
guidelines as a valuable first-line option for metastatic colorectal cancer patients, selected 
according to the pivotal TRIBE study criteria. However, some concerns raised about the use of 
FOLFOXIRI in the daily practice, including the actual benefit of the exposure to all the three 
cytotoxics as compared with the pre-planned sequential administration of the same drugs in 
oxaliplatin- and irinotecan-based doublets, and the feasibility and the efficacy of treatments 
after progression. 
We searched Pubmed on July 30th, 2019, for the terms “FOLFOXIRI”, “triplet”, “doublets”, 
“FOLFOX”, “XELOX”, “FOLFIRI”, “XELIRI”, “bevacizumab”, “reintroduction”, “second-line”, 
“strategy trial”. We found only a few reports that retrospectively described a favourable 
outcome of second-line therapies, including the reintroduction of the triplet, given after 
failure of first-line FOLFOXIRI in non-randomly assigned subgroups, and no trials that 
prospectively compared the efficacy of the upfront use of FOLFOXIRI versus a standard 
sequential strategy of oxaliplatin- and irinotecan-based doublets.  
Herein, we report results of the phase III TRIBE2 study, designed with the purpose to 
investigate whether the upfront use of FOLFOXIRI improves the clinical outcome of 
unresectable metastatic colorectal cancer patients, when compared with the pre-planned, 
sequential use of mFOLFOX6 and FOLFIRI. In both strategies bevacizumab is added upfront 




and after progression, to exploit the effectiveness of a prolonged inhibition of angiogenesis, 
alternating short (up to 4 months) induction periods and less intensive maintenance phases. 
Added value of this study 
Current data provide additional evidence of the impact of the upfront use of FOLFOXIRI plus 
bevacizumab on the survival of unresectable metastatic colorectal cancer patients, 
demonstrating its superiority when compared with a sequential strategy of doublets plus 
bevacizumab.  The efficacy of treatments after progression to FOLFOXIRI plus bevacizumab is 
clearly shown, and the beneficial effect of the reintroduction of the triplet in selected patients 
is suggested for the first time.  
Implications of all the available evidence 
Based on these results upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of 
the same regimen in case of disease progression is the best therapeutic option for metastatic 
colorectal cancer patients who meet the study inclusion criteria and, in particular, for those 
with a right-sided and/or a RAS or BRAF mutated tumour. 
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Data are median (IQR) or number (%). ECOG, Eastern Cooperative Oncology Group; MMR, mismatch repair; MSS: 
microsatellite stable; MSI-low, low microsatellite instability; MSI-high, high microsatellite instability. Control group indicates 
mFOLFOX6 plus bevacizumab, followed after disease progression by FOLFIRI plus bevacizumab. Experimental group indicates 
FOLFOXIRI plus bevacizumab, followed after disease progression by FOLFOXIRI plus bevacizumab. 
  




Table 2. Most common grade ≥3 adverse events occurring during first-line in the safety population 
and during therapy administered after disease progression in the per protocol population, according 
to treatment group. 
AEs, No (%) 
First-line therapy 
Treatment after disease progression 



















Nausea 11 (3%) 20 (6%) 0·140 6 (3%) 8 (6%) 0·263 
Vomiting 5 (2%) 9 (3%) 0·419 4 (2%) 4 (3%) 0·717 
Diarrhoea 18 (5%) 57 (17%) <0·001 12 (6%) 13 (10%) 0·207 
Stomatitis 9 (3%) 15 (5%) 0·299 7 (3%) 6 (5%) 0·774 
Neutropenia 71 (21%) 167 (50%) <0·001 49 (24%) 34 (26%) 0·800 
Febrile 
neutropenia 
10 (3%) 22 (7%) 0·045 3 (1%) 4 (3%) 0·442 
Neurotoxicity 3 (1%) 6 (2%) 0·505 0 6 (5%) 0·004 
Asthenia 19 (6%) 23 (7%) 0·633 12 (6%) 10 (8%) 0·653 
Anorexia 6 (2%) 4 (1%) 0·545 2 (1%) 2 (2%) 0·650 
Arterial 
hypertension 
34 (10%) 25 (7%) 0·223 4 (2%) 4 (3%) 0·717 
Venous 
thromboembolism 
19 (6%) 12 (4%) 0·204 2 (1%) 1 (1%) 1·000 
Data are number (%). AEs: adverse events. First-line therapy: control group indicates induction with mFOLFOX6 plus 
bevacizumab, followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab; experimental group indicates 
induction with FOLFOXIRI plus bevacizumab, followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab. 
Therapy administered per protocol after disease progression: control group indicates induction with FOLFIRI plus 
bevacizumab, followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab; experimental group indicates 
induction with FOLFOXIRI plus bevacizumab, followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab. 








Figure 1. TRIBE2 study consort diagram.  
  
§
 One patient allocated to control group received the experimental study treatment and was included in the experimental 
group in the safety population; *two patients in the control group and three patients in the experimental group died the 
same day of disease progression and were not included in the population for the analysis of 2
nd
 progression-free survival. 
Control group indicates mFOLFOX6 plus bevacizumab, followed after disease progression by FOLFIRI plus bevacizumab. 
Experimental group indicates FOLFOXIRI plus bevacizumab, followed after disease progression by FOLFOXIRI plus 
bevacizumab. FOLFIRI: fluorouracil, L-leucovorin, and irinotecan; FOLFOXIRI: fluorouracil, L-leucovorin, oxaliplatin and 
irinotecan; FOLFOX: fluorouracil, L-leucovorin, and oxaliplatin; bev: bevacizumab; PD, progressive disease.   
679 randomized patients
1 never treated
1§ received experimetal study treatment
2 received other therapy
339 included in the intention to treat
population and randomly assigned to 
experimental group
340 included in the intention to treat
population and randomly assigned to 
control group
1 never treated
3 received other therapy
335 received 1st-line FOLFOXIRI/bev
according to random assignment
336 received 1st-line mFOLFOX6/bev
according to random assignment
298 progressed 277 progressed
12 died before 1st PD 18 died before 1
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259 received a therapy after 1st PD
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according to random assignment
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39 did not receive a therapy after 1st PD
18 died* before 2nd PD
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15 alive before 2nd PD
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45 alive, on follow-up 42 alive, on follow-up
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Kaplan Meier estimates of progression-free survival 2 in the intention to treat population, according to treatment group 
(A). Subgroup analyses of progression-free survival 2 according to clinical and molecular characteristics (B). 
CI, confidence interval; HR, hazard ratio; mos, months; ECOG PS, Eastern Cooperative Oncology Group Performance Status; 
mut, mutated; wt, wild-type; MSS, microsatellite stable; MSI-high, high microsatellite instability. Control group indicates 
mFOLFOX6 plus bevacizumab, followed after disease progression by FOLFIRI plus bevacizumab. Experimental group indicates 
FOLFOXIRI plus bevacizumab, followed after disease progression by FOLFOXIRI plus bevacizumab. 
Control group
Experimental group
HR: 0∙74 [95%CI: 0∙63-0∙88]
p<0∙001
Experimental group (N pts=339)
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Kaplan Meier estimates of 1
st
 progression-free survival in the in the intention to treat population, according to treatment 
group (A). Subgroup analyses of 1
st
 progression-free survival according to clinical and molecular characteristics (B). 
CI, confidence interval; HR, hazard ratio; mos, months; ECOG PS, Eastern Cooperative Oncology Group Performance Status; 
mut, mutated; wt, wild-type; MSS, microsatellite stable; MSI-high, high microsatellite instability. Control group indicates first-
line induction with mFOLFOX6 plus bevacizumab, followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab. 
HR: 0∙74 [95%CI: 0∙63-0∙86]
p<0∙001
Experimental group (N pts=339)
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Experimental group indicates first-line induction with FOLFOXIRI plus bevacizumab, followed by maintenance with 
fluorouracil/L-leucovorin plus bevacizumab. 
  









Kaplan Meier estimates of 2
nd
 progression-free survival in the intention to treat population (i.e., patients alive at the time 
of first-line disease progression), according to treatment group (A). Kaplan Meier estimates of 2
nd
 progression-free survival 
in the per protocol population, according to treatment group (B). 
CI, confidence interval; HR, hazard ratio; mos, months. Panel A. Control group indicates patients candidate to receive after 
disease progression FOLFIRI plus bevacizumab, according to random assignment. Experimental group indicates patients 
candidate to receive after disease progression FOLFOXIRI plus bevacizumab, according to random assignment. Panel B. 





HR: 0∙87 [95%CI: 0∙73-1∙04]
p=0∙116
Experimental group (N pts=274)














HR: 0∙79 [95%CI: 0∙63-1∙00]
p=0∙049
Experimental group (N pts=132)














followed by maintenance with fluorouracil/L-leucovorin plus bevacizumab, as per random assignment. Experimental group 
indicates patients who actually received after disease progression induction with FOLFOXIRI plus bevacizumab, followed by 
maintenance with fluorouracil/L-leucovorin plus bevacizumab, as per random assignment. 
  




Figure 5. Overall survival. 
 
 
Kaplan Meier estimates of overall survival in the intention to treat population, according to treatment group. 
CI, confidence interval; HR, hazard ratio; mos, months. Control group indicates mFOLFOX6 plus bevacizumab, followed after 
disease progression by FOLFIRI plus bevacizumab. Experimental group indicates FOLFOXIRI plus bevacizumab, followed after 






HR: 0∙82 [95%CI: 0∙68-0∙98]
p=0∙032
Experimental group (N pts=339)
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1. INTRODUCTION 
1.1. FOLFOXIRI plus bevacizumab as first-line treatment of unresectable mCRC 
A growing amount of drugs is indicated for the first-line treatment of mCRC and, in 
the absence of contraindications, the association of a biologic agent to a 
chemotherapy backbone is a standard choice as a first-line regimen. The intensity of 
the upfront chemotherapy is a highly debated issue and international guidelines [1,2] 
include one- to three-drugs regimens as possible options according to the treatment’s 
objective (conversion vs palliative intent), disease’s characteristics (indolent vs 
aggressive behaviour, tumor load) and patient’s general conditions and 
comorbidities. Not only the three conventional cytotoxics (fluoropyrimidines, 
oxaliplatin, irinotecan), but also three targeted agents (the anti- Vascular Endothelial 
Growth Factor (VEGF), bevacizumab (bev) and the anti-Epidermal Growth Factor 
(EGFR) monoclonal antibodies, cetuximab and panitumumab) can be used in the first-
line setting. Phase III randomized trials demonstrate that the addition of the 
antiangiogenic bev to first-line fluoropyrimidine-based monochemotherapy [3-5] as 
well as to oxaliplatin- [6] or irinotecan-based doublets [7] provided a significant 
benefit in terms of survival. Metanalyses estimating the magnitude of this benefit 
consistently show a reduction of the risk of death around 20% [8-10]. 
Bev safety profile is now well-known and easily manageable. Phase IV BEAT, BRiTE 
and ARIES trials included more than 5000 patients treated in the daily practice with 
chemotherapy plus bev and indicate that the incidence of bev-related adverse events 
is quite low and includes bleeding (3%), gastrointestinal perforation (1-2%), arterial 
thromboembolism (1-2%), hypertension (5-8%), proteinuria (1%) and wound-
healing complications (1-2%) [11-13].  
More recently, a phase II trial by the G.O.N.O. group evaluated the combination of bev 
with the three-drugs regimen FOLFOXIRI (CPT-11 165 mg/sqm d1, LOHP 85 mg/sqm 
d1, LV 200 mg/sqm d1 and 5-FU 3200 mg/sqm infusion over 48h). Cycles were 
repeated every 2 weeks, for a total of 12 cycles, followed by a maintenance treatment 
with 5-FU/LV and bev. According to a Phase II single-stage Fleming design, assuming 
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a null hypothesis of 10 months-progression free rate (10m-PFR) of 50% and an 
alternative hypothesis of 10m-PFR of 70%, with alpha and beta-errors of 0.05 and 
0.10, the experimental treatment would have been judged to be promising if at least 
33 patients, out of 53 evaluable, had been free of progression at 10 months. 
At a median follow-up of 28.8 months, 42 (74%) out of 57 treated patients were 
actually free of progression at 10 months, with a median PFS of 13.1 months and a 
median OS of 30.9 months. In terms of activity, promising results were reported, with 
a RR of 77% and a disease control rate of 100%. Such a considerable activity 
translated into a radical resection rate of 26%, rising to 40% among patients with 
liver-only metastases. A pCR was observed in 20% of patients who underwent radical 
resection. The safety profile was absolutely consistent with expected toxicities and no 
unforeseen adverse events were reported [14]. 
Based on these promising findings the phase III TRIBE trial was designed. Five-
hundred-eight unresectable mCRC patients were randomly assigned to receive up to 
12 cycles of FOLFOXIRI plus bev or FOLFIRI plus bev, both followed by 5FU/LV plus 
bev until disease progression. Primary endpoint was PFS. Patients treated with 
FOLFOXIRI plus bev achieved a significantly longer PFS (12.1 vs 9.7 months, stratified 
HR: 0.75 [0.62-0.90], p=0.003) and a higher response rate (65% vs 53%, p=0.006). No 
significant differences in terms of secondary resection rate with radical intent were 
observed (26% vs 21%, p=0.327). A preliminary analysis, at a median follow up of 
32.2 months, evidenced a trend toward longer OS in the experimental arm (31.0 vs 
25.8 months, stratified HR: 0.79 [0.63-1.00], p=0.054). 
The safety profile was consistent with results from the previous phase III trial by the 
G.O.N.O. group of FOLFOXIRI vs FOLFIRI. The triplet was associated with increased 
grade 3/4 neutropenia (50% vs 20%), diarrhea (19% vs 11%) and stomatitis (9% vs 
4%) but not with higher incidence of febrile neutropenia (9% vs 6%). Bev-related 
adverse events were in the expected range. The incidence of serious adverse events 
(20.4% vs 19.7%) and treatment-related deaths (2.4% vs 1.6%) was not significantly 
different between treatment arms [15].  
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Previous impressive results achieved by the triplet FOLFOXIRI in terms of activity 
and secondary resections led to consider such an intensive upfront regimen as a 
preferable choice also when a remarkable tumor shrinkage is needed. Indeed, this 
suggestion has been recently confirmed by phase II OLIVIA trial [16], that 
randomized 80 mCRC patients with liver-only metastases, defined as initially 
unresectable by a multidisciplinary team, to receive FOLFOX plus Bev or FOLFOXIRI 
plus Bev. Overall (R0/R1/R2) resection rate, the primary endpoint, was numerically 
higher in the FOLFOXIRI plus bev arm (61.0% vs 48.7%, p=0.271). The triplet plus 
bev allowed to achieve an higher R0 resection rate (48.8% vs 23.1%, p=0.017) and an 
impressively higher ORR (80.5% vs 61.5%, p=0.061), with a substantial benefit also 
in terms of PFS (18.8 vs 12.0 months, p=0.0002). 
1.2. Continuation of bevacizumab beyond progression in mCRC 
More than ten years ago, preclinical experiences suggested the potential efficacy of a 
sustained antiangiogenic strategy beyond the first occurrence of resistance. Results 
from the observational studies BRiTE and ARIES provided initial clinical data in 
support of this hypothesis. In particular, in the large US prospective observational 
cohort study BRiTE 642 (44.4%) out of 1445 patients who had experienced 
progressive disease, received bev beyond progression, while 531 (36.7%) received no 
bev beyond progression [12]. A significant advantage in terms of survival beyond first 
progression (SBP) was noted with this strategy, that was still significant after 
adjusting for other prognostic factors (HR:0.49 [0.41-0.58], p<0.001). Similar results 
were provided by the ARIES observational study. Among 539 out of 1097 patients 
who received bev beyond progression significantly longer SBP was observed, 
compared to 417 patients who did not. Results provided by the multivariate model 
were consistent with those from BRiTE trial (HR: 0.41 [0.34-0.49], p<0.001) [17]. 
More recently, a phase III trial, named TML (Treatment across Multiple Lines - 
ML18147) was conducted in Europe and Saudi Arabia, randomizing mCRC patients 
previously treated with bev plus standard first-line chemotherapy to cross-over 
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chemotherapy with or without bev. Enrolled patients had experienced progressive 
disease less than 4 weeks prior to start of study treatment. Primary endpoint was OS. 
The use of bev beyond progression provided a significant advantage in terms of OS 
(11.2 vs 9.8 months, HR: 0.81 [0.69-0.94], p=0.0062) and PFS (5.7 vs 4.1 months, HR: 
0.68 [0.59-0.78], p<0.0001), while no differences in response rate were reported 
(5.4% vs 3.9%, p=0.311). Adverse events were consistent with the expected toxicity 
profile of bev. As expected, the advantage provided by the addition of bev was 
independent of the KRAS mutational status [18-19]. 
Another phase III study with a similar design, the BEBYP (Bevacizumab BeYond 
Progression) trial, was contemporaneously conducted in Italy and prematurely 
stopped when results from TML were released. Primary endpoint was PFS. The 
continuation of bev beyond progression provided a significant advantage in terms of 
PFS (6.8 vs 5.0 months, HR: 0.72 [0.54-0.97], p=0.0029), while no differences in 
response rate (21% vs 18%, p=0.71) or OS (14.1 vs 15.5 months, HR: 0.77 [0.56-1.07], 
p=0.12) were reported. Nevertheless, the trial was clearly underpowered to detect an 
advantage in terms of survival [20]. 
Consistent results from both trials demonstrated the efficacy of a prolonged 
antiangiogenic strategy and identified the prosecution of bev in combination with a 
switched chemotherapy as a reasonable option for the second-line treatment of mCRC 
patients who have already received a bev-containing first-line regimen. 
1.3. Induction and maintenance phases in the era of targeted agents 
Recent evidences point out the correlation of the early objective response with 
survival in mCRC, thus highlighting the potential influence of the early tumor 
shrinkage on the subsequent steps of disease history. These findings also underscore 
the importance of achieving a relevant tumor shrinkage early after an intensive 
upfront treatment.  
At the same time, the optimal duration of chemotherapy and Bev is still a matter of 
debate and some trials indicate that the possibility to alternate on-chemo and chemo-
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free intervals is a reasonable option. Phase III randomized OPTIMOX1 (21), 2 (22), 
COIN (23) and GISCAD (24) trials addressed this issue, substantially evidencing that 
the choice not to continuously administer the treatment until the evidence of disease 
progression, but to alternate periods of less intensive chemotherapy or chemo-
holidays can be pursued without compromising patients’ prognosis.  
Nowadays, in the targeted agents’ era, a heated issue concerns the importance of the 
so called “maintenance” treatment, that is the choice to pursue the antiangiogenic 
until disease progression, also in the case of a partial or total interruption of the 
associated chemotherapy. SAKK 41/06 study is a non-inferiority trial that 
randomized 262 patients that did not progress after 4-6 months of chemotherapy 
plus Bev, to continue or not Bev alone until disease progression. The non-inferiority 
of the observation strategy was not demonstrated in terms of time to progression 
(TTP) or OS. Patients treated with Bev reported a 1.2 months absolute advantage in 
TTP (4.1 vs 2.9 months from randomization, HR: 0.74 [0.57-0.95], p for non-
inferiority=0.470) and a 3.3 months advantage in OS (26.1 vs 22.8 months, HR: 0.83 
[0.61-1.12], p for difference=0.218) (25). 
In CAIRO-3 trial, patients achieving a disease stabilization or response after six cycles 
of CAPOX plus Bev were randomized between observation or maintenance treatment 
with capecitabine plus Bev. Upon the first disease progression, CAPOX plus bev had to 
be reintroduced and continued until the second evidence of disease progression. The 
primary endpoint was the PFS2, defined as the time from randomization to 
progression upon re-introduction of CAPOX plus bev. Patients in the maintenance 
arm achieved a significant benefit in terms of PFS2 (11.8 vs 10.5 months, HR: 0.81 
[0.67-0.98], p=0.028), PFS (8.5 vs 4.1 months, HR: 0.44 [0.36-0.53], p<0.00001) and a 
non-significant advantage in OS (21.7 vs 18.2 months, HR: 0.87 [0.71-1.06], p=0.156) 
that becomes significant in the adjusted analysis (HR: 0.80, p=0.035) (26). 
On the basis of these evidences, the opportunity to alternate induction and 
maintenance phases in the disease history of mCRC patients is considered a valuable 
option. 
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2. STUDY RATIONALE 
 Bev improves the efficacy of first-line chemotherapy in unresectable mCRC. 
 In the phase III TRIBE trial upfront FOLFOXIRI plus bev provided a significant 
advantage in terms of PFS and RR compared to FOLFIRI plus bev. A trend toward 
better OS was also evidenced. The second-line treatment was at investigator’s choice. 
A manageable increase in diarrhea, mucositis and neutropenia was reported, while no 
differences in febrile neutropenia, serious adverse events and toxic deaths were 
evidenced. 
 A growing amount of data support the clinical relevance of achieving an early and 
deep tumor shrinkage.  
 Phase III TML and BEBYP trials demonstrated that the continuation of bev 
beyond disease progression combined with a switched chemotherapy regimen 
provided a significant advantage in terms of OS and PFS. 
 Based on recent evidences, the partial interruption of the upfront “induction” 
chemotherapy before disease progression and the prosecution of bev until disease 
progression as maintenance treatment is a valid strategy in the treatment of mCRC. 
 
On the basis of these considerations, a first-line doublet plus bev followed by a 
second-line switched doublet (from oxaliplatin to irinotecan and viceversa) plus bev 
should be considered a standard option for mCRC patients. Only retrospectively 
collected data are currently available about the efficacy of first-line FOLFOXIRI plus 
bev followed by second-line rechallenge with FOLFOXIRI plus bev. We therefore 
designed the present phase III randomized trial of first-line FOLFOXIRI plus bev 
followed by reintroduction of FOLFOXIRI plus bev at progression versus FOLFOX plus 
bev followed by FOLFIRI plus bev at progression in first- and second-line treatment of 
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3. STUDY DESIGN 
This is a prospective, open-label, multicentric phase III randomized trial in which 
initially unresectable and previously untreated mCRC patients will be randomized to 
receive: 
 









The third- and subsequent lines of treatment will be at investigators’ choice.  
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4. STUDY OBJECTIVES 
4.1. Primary objective 
The main objective of this trial is to compare the efficacy of the two proposed 
treatment strategies in terms of duration of Progression Free Survival 2 (PFS2). 
4.2. Secondary objectives 
Secondary objectives of this study are to compare the two proposed treatment 
strategies in terms of: 
 Duration of Progression Free Survival (PFS); 
 Duration of 2nd-Progression Free Survival (2nd-PFS); 
 Duration of Time to Failure of Strategy (TFS); 
 Duration of Overall Survival (OS); 
 Distribution of Objective Response Rate (ORR) during first- and second-line 
treatment;  
 Distribution of Early Objective Response (EOR) during first-line treatment; 
 Distribution of the rate of secondary R0 resection of metastases;  
 Safety profile;  
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5. PATIENTS’ SELECTION 
5.1. Inclusion criteria 
 Histologically proven diagnosis of colorectal cancer 
 Initially unresectable metastatic colorectal cancer not previously treated with 
chemotherapy for metastatic disease 
 At least one measurable lesion according to RECIST1.1 criteria 
 Availability of a tumoral sample 
 Male or female of 18-75 years of age 
 ECOG PS < or = 2 if aged < 71 years, ECOG PS = 0 if aged 71-75 years 
 Life expectancy of at least 12 weeks 
 Previous adjuvant chemotherapy allowed only if with fluoropyrimidine 
monotherapy and more than 6 months elapsed between the end of adjuvant and first 
relapse 
 Neutrophils >1.5 x 109/L, Platelets >100 x 109/L, Hgb >9 g/dl 
 Total bilirubin 1.5 time the upper-normal limits (UNL) of the normal values and 
ASAT (SGOT) and/or ALAT (SGPT) <2.5 x UNL (or <5 x UNL in case of liver 
metastases) alkaline phosphatase <2.5 x UNL (or <5 x UNL in case of liver metastases) 
 Creatinine clearance >50 mL/min or serum creatinine 1.5 x UNL 
 Urine dipstick of proteinuria <2+. Patients discovered to have 2+ proteinuria on 
dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must 
demonstrate <1 g of protein/24 hr 
 Women of childbearing potential must have a negative blood pregnancy test at 
the baseline visit. For this trial, women of childbearing potential are defined as all 
women after puberty, unless they are postmenopausal for at least 12 months, are 
surgically sterile, or are sexually inactive. 
 Subjects and their partners must be willing to avoid pregnancy during the trial 
and until 6 months after the last trial treatment. Male subjects with female partners of 
childbearing  potential and female subjects of childbearing potential must, therefore, 
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be willing to use adequate contraception as approved by the investigator (barriere 
contraceptive measure or oral contraception) 
 Will and ability to comply with the protocol 
 Written informed consent to study procedures and to molecular analyses.  
5.2. Exclusion criteria 
 Radiotherapy to any site within 4 weeks before the study 
 Previous adjuvant oxaliplatin-containing chemotherapy  
 Previous treatment with bevacizumab  
 Untreated brain metastases or spinal cord compression or primary brain 
tumours 
 History or evidence upon physical examination of CNS disease unless adequately 
treated 
 Symptomatic peripheral neuropathy > 2 grade NCIC-CTG criteria 
 Serious, non-healing wound, ulcer, or bone fracture 
 Evidence of bleeding diathesis or coagulopathy 
 Uncontrolled hypertension and prior histor of hypertensive crisis or 
hypertensive encephalopathy 
 Clinically significant (i.e. active) cardiovascular disease for example 
cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable 
angina, New York Heart Association (NYHA) grade II or greater congestive heart 
failure, serious cardiac arrhythmia requiring medication 
 Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or 
recent arterial thrombosis) within 6 months of study enrolment. 
 Any previous venous thromboembolism > NCI CTCAE Grade 3. 
 History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI 
bleeding within 6 months prior to the first study treatment. 
 Current or recent (within 10 days prior to study treatment start) ongoing 
treatment with anticoagulants for therapeutic purposes 
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 Chronic, daily treatment with high-dose aspirin (>325 mg/day) 
 Treatment with any investigational drug within 30 days prior to enrollment or 2 
investigational agent half-lives (whichever is longer) 
 Other co-existing malignancies or malignancies diagnosed within the last 5 years 
with the exception of localized basal and squamous cell carcinoma or cervical cancer 
in situ 
 Major surgical procedure, open biopsy, or significant traumatic injury within 28 
days prior to study treatment start, or anticipation of the need for major surgical 
procedure during the course of the study 
 Lack of physical integrity of the upper gastrointestinal tract, malabsorption 
syndrome, or inability to take oral medication 
 Pregnant or lactating women. Women of childbearing potential with either a 
positive or no pregnancy test at baseline. Postmenopausal women must have been 
amenorrheic for at least 12 months to be considered of non-childbearing potential. 
Sexually active males and females (of childbearing potential) unwilling to practice 
contraception (barriere contraceptive measure or oral contraception) during the 
study and until 6 months after the last trial treatment.  
5.3 Discontinuation Criteria 
A patient may be discontinued from the clinical trial at any time for any reason. 
It is the right and the duty of the investigator to stop treatment in any case in which 
emerging effects are of unacceptable risk to the individual subject. In addition, 
patients have the right to voluntarily discontinue study treatment or withdraw from 
the study at any time for any reason. In instances where consent is withdrawn, the 
Investigator must clarify whether the patient is willing to continue to be followed (i.e. 
for survival). 
 
Reasons for discontinuation of study treatment may include, but are not limited to, 
the following: 
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• Any medical condition that at the judgement of the Investigator or of the Sponsor 
may jeopardise patient‘s safety if he or she continues on study treatment; 
• Major protocol violation (i.e. affecting the patients’ safety); 
• Investigator or Sponsor determines it is in the best interest of the patient; 
•  Patient’s non-compliance to the protocol; 
•  Patient withdrawal of consent. 
 
Reasons for withdrawal from the study may include, but are not limited to, the 
following: 
•  Patient withdrawal of consent; 
•  Patient lost to follow-up; 
•  Death. 
5.4 Replacement of Subjects 
A subject who discontinues from the trial will not be replaced.  
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6. PARTICIPATING CENTERS, ENROLLMENT AND STUDY TIMELINE 
About 60 Italian Oncology Units will participate to the trial. 654 patients will be 
randomized. 
The registration and randomization procedures will be centralized at Clinical Trials 
Coordinating Center - Istituto Tosca++no Tumori. 
Patients considered eligible and who have signed a written informed consent will be 
randomly assigned to one of the two treatment arms in a 1:1 ratio. Eligible patients 
will be stratified according to center, ECOG PS (0 vs 1, 2), primary tumor location 
(right vs left or rectum) and previous adjuvant chemotherapy (yes vs no). 
The randomization will be performed by using an electronic WEB-based system. 
The randomization code will consist of a unique identification code. This code must 
be used on all further documentation and correspondence, including electronic case 
record forms (e-CRFs). e-CRFs fac-simile are provided as a separate addendum to this 
study protocol. 
It is responsibility of the principal investigator to ensure that each patient is eligible 
for the study before requesting randomization. 
Study length is planned to be about 4.5 years since the enrollment is expected to be 
about 3 years, with a minimum period of follow-up of 18 months.  
The end of study is defined as the time when all randomized patients will have 
experienced the second evidence of disease progression or will be out of treatment as 
per protocol, toxicity or medical decision. 
 
The planned study timeline is as follows: 
1. Submission date to health authority / ethics: November 2014 
2. First Patient In: December 2014 
3. Enrollment rate: 200 pts/year 
4. Last Patient In: December 2017 
5. Last Patient Last Visit: May 2019 
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6. Preliminary data on ORR and safety will be reported with no comparative intent 
when 150, 300 and 450 patients will have been randomized. This will happen 
approximately after 18, 27 and 36 months from the first patient in, respectively.  
7. Efficacy interim analysis on primary endpoint: after 303 events (early 2018) 
8. First data release on PFS2: Early 2020 
9. Manuscript submission: Late 2020 
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7. STUDY TREATMENT AND PROCEDURES 
7.1. Study treatment 
Eligible patients will be randomized to receive: 
Arm A 
mFOLFOX-6 plus bev 
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluoruracil 400 mg/sqm iv bolus, day 1 
 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1 
to be repeated every 2 weeks for a maximum of 8 cycles.  
 
If no progression occurs, patients will receive maintenance 5-FU/LV plus bev at the 
same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be 
repeated biweekly until disease progression, unacceptable toxicity or patient’s 
refusal. 
The prosecution of bev until disease progression is recommended also in the case of 
interruption of 5-fluoruracil because of adverse events, patient’s refusal or 
investigator’s choice. 
 
At the time of disease progression patients will receive FOLFIRI plus bev* 
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Irinotecan 180 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluoruracil 400 mg/sqm iv bolus, day 1 
 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1 
to be repeated every 2 weeks for a maximum of 8 cycles.  
*Doses may be modified according to patient’s tolerance to 1st-line regimen. 
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If no progression occurs, patients will receive maintenance 5-FU/LV plus bev at the 
same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be 
repeated biweekly until disease progression, unacceptable toxicity or patient’s 
refusal. 
The prosecution of bev until disease progression is recommended also in the case of 




FOLFOXIRI plus bev 
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 
 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 
to be repeated every 2 weeks for a maximum of 8 cycles.  
 
If no progression occurs during FOLFOXIRI plus bev, patients will receive 
maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction 
treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, 
unacceptable toxicity or patient’s refusal. 
The prosecution of bev until disease progression is recommended also if 5-
fluorouracil is interrupted because of adverse events, patient’s refusal or 
investigator’s choice. 
 
At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at 
the same doses and schedule previously tolerated, for a maximum of 8 cycles. In the 
case of  persistent neurotoxicity ≥ G2, FOLFIRI plus bev will administered for a 
maximum of 8 cycles. 
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If no progression occurs during FOLFOXIRI plus bev, patients will receive 
maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction 
treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, 
unacceptable toxicity or patient’s refusal. 
The prosecution of bev until disease progression is recommended also in the case of 
interruption of 5-fluorouracil because of adverse events, patient’s refusal or 
investigator’s choice. 
7.2. Secondary resection of metastases  
Surgical radical resection of residual metastases in responsive patients is highly 
recommended and its feasibility should be evaluated every 2 months. It is strongly 
recommended to assess patients’ resectability in the frame of a multidisciplinary 
group with a good expertise in the management of mCRC.  
At least 5 weeks should elapse between the last administration of bev and the day of 
surgery. After resection, patients will receive post-operative therapy for 6 months (12 
cycles) possibly up to 12 cycles of the same chemotherapy plus Bev regimen received 
before resection followed by 5FU/LV plus bev up to a total of 12 post-operative cycles 
(including chemotherapy plus Bev and 5FU/LV plus Bev). Post-operative treatment 
should start not earlier than 4 weeks after surgery. In the case of repeated 
procedures, post-operative treatment should start not earlier than 4 weeks after the 
last procedure. The choice to administered additional cycles of systemic treatment 
between two procedures of a pre-planned 2 stage-surgery is at investigator’s choice. 
 
 




If disease progression occurs more than 1 year after the completion of the post-
operative therapy, the second-line treatment according to the randomization arm is 
still recommended but it will be considered out of study . 
7.3. Baseline and on treatment clinical evaluations 
At baseline: 
 Medical history, ECOG PS, physical examination (including height and weight, 
blood pressure and heart rate); 
 ECG; 
 Complete blood examination: blood count and differential, bilirubin (total and 
direct), AST, ALT, alkaline phosphatase, albumin, LDH, serum creatinine, glucose, 
electrolytes (sodium, potassium, calcium), International normalized ratio 
(INR)/Activated partial Thromboplastin Time (APTT), CEA, CA19.9; pregnancy test (if 
clinically indicate); 
 Urinanalysis; 
 Contrast-Enhanced chest and abdominal CT scan, or Abdomen MRI and Chest CT 
if contrast-enhanced CT scan is contraindicated. To be performed no more than 28 
days before randomization; 
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 Collection of a copy of baseline CT scan (and/or abdomen MRI), digitally stored 
on CD-ROM; 
 Obtained written informed consent; 
 Collection of a paraffin-embedded block of the primary tumor and/or metastases, 
or 10 slides 5 m-thick for immunohystochemistry and 10 slides 8 m-thick; 
 Collection of blood and plasma samples. 
Before every cycle of treatment (induction or maintenance), until the 2nd 
evidence of PD: 
 Partial blood examination: Blood count and differential, bilirubin (total and 
direct), serum creatinine, INR/APTT (only for patients on anticoagulation therapy); 
 Dipstick proteinuria; 
 Collection of reported adverse events; 
 ECOG PS, physical examination (including height, weight, blood pressure and 
heart rate). 
Every 8 weeks until the 2nd evidence of PD: 
 Complete blood examination: Blood count and differential, bilirubin (total and 
direct), AST, ALT, alkaline phosphatase, albumin, LDH, serum creatinine, glucose, 
electrolytes (sodium, potassium, calcium), INR/APTT, CEA, CA19.9; 
 Contrast-Enhanced chest and abdominal CT scan, or Abdomen MRI and Chest CT 
if contrast-enhanced CT scan is contraindicated (the same technique used in the 
baseline assessment); 
 Collection of blood and plasma samples. 
At the end of the treatment and after the 2nd evidence of PD (visits scheduled 
according to investigator’s practice): 
 ECOG PS, physical examination (including height, weight, blood pressure and 
heart rate); 
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 Follow up on adverse events still ongoing at the time of 2nd PD; 
 Survival follow up. 
7.4. Tissue specimens collection  
The collection of tissue specimens is mandatory for study entry. A paraffin-embedded 
block of the primary tumor and/or metastases if available, or 10 slides 5 m-thick for 
immunohystochemistry and 10 slides 8 m-thick for molecular biology analyses, are 
required.  
Tissue specimens will be sent, together with the accompanying histological report, to 
the Coordinating Center (U.O. Oncologia Medica 2 Universitaria – Azienda 
Ospedaliero-Universitaria Pisana), where they will be collected and adequately stored 
under the responsability of Dr. Loupakis.  
  
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3478102 
 27 
7.5. Blood sampling collection 
Three 6ml EDTA tubes will be collected once at anytime before or during the 
treatment. They will be labelled as “TRIBE2 - Patient Code/ SNP Blood” (see fac-
simile) and will be stored at -20°C until shipment to the Coordinating Center (U.O. 




In addition, four 6 ml EDTA tubes will be collected at the following time-points: 
 at baseline (Bas) 
 at the first evidence of PD (PD1) 





One tube will be labelled as “TRIBE2 - Patient Code/ Date/ Bas or PD1 or PD2/Blood” 
(see fac-simile) and directly stored at -80°C until shipment to the Coordinating Center 
(U.O. Oncologia Medica 2 Universitaria – Azienda Ospedaliero-Universitaria Pisana). 
 
Three tubes will be centrifuged as soon as possible at room temperature at 1600 g x 
10 minutes and plasma supernatant will be collected and divided into four aliquots. 
Two aliquots will be stored at -80°C until shipment to the Coordinating Center in 
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tubes labelled as “TRIBE2 – Patient Code/ Date/ Bas or PD1 or PD2/ Plasma F” (see 
fac-simile). 
The other 2 aliquots will be centrifuged at room temperature at 3000 g x 10 minutes 
and plasma supernatant will be collected in tubes labelled as “TRIBE2 – Patient Code/ 





The shipment of blood samples will be arranged by the G.O.N.O. that will provide dry 
ice for the shipment.  
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7.6. Collection of CT scan images  
Tumor response will be assessed throught contrast-enhanced chest and abdomen CT 
scans with a contiguous slice thickness of ≤ 7mm, that will be performed in the 
radiology department of the study site. Abdomen MRI and chest CT scan are allowed 
in the case of contraindications to the use of iodine contrast agents.  
In the case of clinical suspicion of disease progression, the radiographic evaluation 
should be performed within a maximum of 7 days to confirm objective disease 
progression. 
CD-ROM copies of the CT scans at baseline, at the time of the best response during the 
first treatment, at the time of the first and second evidence of PD will be collected at 
the Coordinating Center (U.O. Oncologia Medica 2 Universitaria – Azienda 
Ospedaliero-Universitaria Pisana) for central review.  
Site should follow their local privacy practices to de-identify all sybject identifying 
information (name, medical record number, ect.) prior to submitting images to 
Coordinating Center. 
Upon receipt, the Coordinating Center will verify that this information has been 
completely redacted, and, if necessary, will redact any remaining identifying 
information. 
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1. Until the 2nd evidence of disease progression 
2. Blood count and differential, bilirubin (total and direct), AST, ALT, alkaline phosphatase, albumin, 
LDH, serum creatinine, glucose, electrolytes (sodium, potassium, calcium), International normalized 
ratio (INR)/Activated partial Thromboplastin Time (APTT), CEA, CA19.9; pregnancy test (if clinically 
indicate); 
3. Blood count and differential, bilirubin (total and direct), serum creatinine, INR/APTT (only for 
patients on anticoagulation therapy); 
4. Only a the first and second evidence of PD 
5. AE assessment to be started after signing of IC until 30 days after last study treatment 





















































































Informed Consent X     
Complete medical history X     
Inclusion/Exclusion Criteria Checked X     
Tumor assessment (total-body CT or 
abdomen MRI + chest CT) 
X   X  
Collection of a CD-ROM copy of CT 
scan 
X   X  
12-lead ECG X     
ECOG PS X X X X  
Physical examination X  X X  
Complete blood examination2 X   X  
Partial blood examination3  X X   
Dipstick proteinuria X X X   
Collection of a paraffin-embedded 
tissue sample X 
    
Collection of blood samples  X  X
4  
Adverse events and toxicity   X
5  X6 
Survival follow up     X 
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8. SAFETY ISSUES 
8.1. Dose reductions and delays 
Toxicities should be evaluated according to CTCAEv4.0. Once a dose has been reduced 
it should not be increased at a later time. 
 
Dose modifications for toxicities attributable to chemotherapy 
 
TOXICITY AT THE START OF 




Irinotecan Oxaliplatin 5FU 
WBC < 3.000/mm3 
Hold until resolution 
Neutrophils < 1.000/mm3 
Platelets < 100.000/mm3 
Diarrhea > 1 
Mucositis > 1 
Any other non-hematological toxicity > 2 
Hand/foot syndrome 3-4 100% 100% STOP 
Neurotoxicity > 3 100% STOP 100% 
 
PREVIOUS TOXICITY GRADE Irinotecan Oxaliplatin 5FU 
Neutropenia >5 days 4 
75% 75% 100% Febrile Neutropenia 4 
Thrombocytopenia 3-4 
Diarrhea 3 75% 100% 75% 
Diarrhea 4 50% 100% 50% 
Stomatitis 3 100% 100% 75% 
Stomatitis 4 100% 100% 50% 
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Dose modifications for toxicities attributable to bevacizumab 
 
Event Grade Adjustment to bev 
Hypertension 
3 
If not controlled by 3-drug medication, 
permanently discontinue 




Any grade CNS Permanently discontinue 
≥2  
(pulmonary) 





3 Hold temporarily 
4 Permanently discontinue 
Arterial 
thrombosis 
Any Grade Permanently discontinue 
Congestive Heart 
Failure 




- For 2+ dipstick: may administer bev, obtain 24-
hour urine sample prior to next bev dose 
Suspend bev for ≥2 g /24 hours and resume when 
proteinuria is <2 g /24 hours and protein 
creatinine ratio <2.0 
- For 3+ dipstick: obtain 24 hour urine sample 
prior to bev administration 
Suspend bev for ≥2 g /24 hours and resume when 
proteinuria is <2 g /24 hours and protein 
creatinine ratio <2.0 
4 Permanently discontinue  
GI perforation Any grade Permanently discontinue  
 PRES/RPLS Any grade Permanently discontinue 
Fistula 
Any grade TE fistula Permanently discontinue  








3 Hold until recovery to ≤ Grade 1  
4 Permanently discontinue 
 




Bevacizumab should be permanently discontinued in patients who develop 
gastrointestinal perforation. 
Fistula 
Bevacizumab should be permanently discontinued in patients who develop any grade 
tracheoesophageal and temporarily hold or permanently discontinued in the case of 
grade ≥ 2 fistula in any other site. 
Surgical Procedures/Wound Healing Complications 
Bevacizumab therapy should not be initiated for at least 28 days following major 
surgery or until the surgical wound is fully healed. In patients who experience wound 
healing complications during bevacizumab treatment, bevacizumab should be 
withheld until the wound is fully healed. 
Bevacizumab therapy should be withheld 60 days before elective surgery. CVAD 
placement and complications will be monitored as an assessment of treatment-
related complications. Date of placement of CVAD will be noted in the medical record 
and recorded in the eCRF. Episodes of CVAD removal or replacement will be 
recorded. Episodes of CVAD-related thrombosis, infection, or dysfunction will be 
recorded. 
Necrotising fasciitis including fatal cases, has rarely been reported in patients treated 
with bevacizumab; usually secondary to wound healing complications, 
gastrointestinal perforation or fistula formation.  Bevacizumab should be 
discontinued in patients who develop necrotising fasciitis, and appropriate treatment 
should be promptly initiated. 
Hypertension 
Patients should be monitored for the development or worsening of hypertension via 
frequent blood pressure measurement. Blood pressure measurements should be 
taken after the patient has been in a resting position for ≥ 5 minutes. Repeat 
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measurements of blood pressure for verification should be undertaken if the initial 
reading is ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic blood pressure. 
• Grade 1 hypertension: Asymptomatic, transient (< 24 hrs) increase by > 20 mmHg 
(diastolic) or to > 150/100 mmHg if previously within normal limits. Intervention not 
indicated. 
• Grade 2 hypertension: Recurrent or persistent (> 24 hr) or symptomatic increase by 
> 20 mmHg (diastolic) or to > 150/100 mmHg if previously within normal limits. 
Monotherapy with ACE-inhibitor may be indicated. Once controlled to < 150/100 
mmHg, patients may continue bevacizumab therapy. 
• Grade 3 hypertension: Requiring more than one anti-hypertensive or more 
intensive therapy than previously. Addiction of diuretic to ACE-inhibitor may be 
indicated; if hypertension is not controlled a third anti-hypertensive drug (calcium 
channel blocker) should be added. 
Bevacizumab should be withheld for persistent or symptomatic hypertension and 
should be permanently discontinued if hypertension is not controlled with triple-
drug medication. 
Proteinuria 
All patients will have a dipstick urinalysis or 24 hour protein determination 
performed within 48 hours prior to the first bevacizumab dose and thereafter every 8 
weeks. Adjustment of bevacizumab administration for proteinuria of ≥ 2 g/24h will 
occur according to the following guidelines, listed below: 
 < 2+ (dipstick): no additional evaluation is required. 
 ≥ 2+ (dipstick): Collect 24-hour urine to determine the total protein within 3 days 
prior to the next scheduled dose: 
- 24-hour proteinuria ≤ 2 g: Administer bevacizumab as scheduled. 
- 24-hour proteinuria > 2 g: Bevacizumab treatment should be withheld pending 
next 24 hour total protein. 
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Repeat 24-hour urine protein ≤ 2 g: Administer bevacizumab as schedule. 24-hour 
protein should be further monitored prior to each administration of bevacizumab 
until it has decreased to ≤ 1 g/24h. 
Repeat 24-hour urine protein > 2 g: Bevacizumab dose should be withheld until 24-
hour protein has decreased to ≤ 2 g. 24-hour protein should be further monitored 
prior to each administration of bevacizumab until it has decreased to ≤ 1 g/24 h. 
Nephrotic syndrome (Grade 4, CTCAEv4.0): Discontinue bevacizumab treatment. 
Thrombosis/Embolism 
All toxicity will be graded according to CTCAEv4.0 guidelines. For patients who 
develop thrombosis/embolism the following action is recommended: 
Bevacizumab should be permanently discontinued in patients who develop arterial 
thromboembolic events of any grade and in patients to develop grade 3 venous 
thrombosis 
Congestive heart failure 
Caution should be exercised when treating patients with clinically significant 
cardiovascular disease or pre-existing congestive heart failure with bevacizumab, 
such as pre-existing coronary heart disease or concomitant cardiotoxic therapy. 
Events consistent with congestive heart failure were reported in clinical trials with 
symptoms ranging from asymptomatic declines in left ventricular ejection fraction to 
symptomatic congestive heart failure, requiring treatment or hospitalisation. Patients 
developing ≥ G3 congestive heart failure should permanently discontinue 
bevacizumab treatment. 
Haemorrhage 
Patients who develop grade ≥2 pulmonary or CNS (any grade) or grade ≥3  
hemorrhage should discontinue bevacizumab treatment. 
Patients who develop grade 3 non-pulmonary and non – CNS hemorrhage should hold 
bevacizumab until all of the following criteria are met: 
 The bleeding has resolved and haemoglobin is stable. 
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 There is no bleeding diathesis that would increase the risk of therapy. 
 There is no anatomic or pathologic condition that significantly increases the risk 
of hemorrhage recurrence. 
Posterior Reversible Encephalopathy Syndrome (PRES/RPLS) 
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8.2. Concomitant medications and management of specific adverse events  
Acute colinergic syndrome 
Atropine sulfate can be used, at the discretion of the investigator, as secondary 
prophylaxis or therapy of early onset cholinergic syndrome induced by irinotecan. 
Secondary prophylactic or therapeutic administration of 0.25-1 mg of subcutaneous 
atropine can be considered (unless clinically contraindicated) in patients 
experiencing rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, 
abdominal cramping, or diarrhea (occurring during or shortly after infusion of 
irinotecan). 
Antiemetic prophylaxis 
To be chosen on the basis of the chemotherapy regimen according to the center’s 
guidelines. 
Diarrhea 
Irinotecan can induce both early and late forms of diarrhea that appear to be 
mediated by different mechanisms. Early diarrhea (occurring during or shortly after 
infusion of irinotecan) is cholinergic in nature. It is usually transient and only 
infrequently is severe. It may be accompanied by symptoms of rhinitis, increased 
salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis 
that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms 
may be ameliorated by administration of atropine (0.25 mg SC). Atropine should not 
be given prophylactically during cycle 1. 
Late diarrhea (generally occurring more than 24 hours after administration of 
irinotecan) can be prolonged, may lead to dehydration and electrolyte imbalance, and 
can be lifethreatening. Patients and patients' caregivers should be carefully informed 
of possible severe toxic effects such as diarrhea and abdominal cramps. Each patient 
should be instructed to have loperamide readily available and to begin treatment for 
late diarrhea (generally occurring more than 24 hours after administration of 
irinotecan) at the first episode of poorly formed or loose stools or the earliest onset of 
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bowel movements more frequent than normally expected for the patient. The patient 
should also be instructed to notify the Investigator if diarrhea or abdominal cramps 
occur. If diarrhea persists for more than 24 hours despite loperamide, the patient 
should be instructed to take a fluoroquinolone antibiotic and to re- contact the 
treating Investigator. The patient should be hospitalised for parenteral support and 
loperamide should be replaced by another anti-diarrheal treatment (e.g. octreotide). 
Patients should have a supply of fluoroquinolone antibiotic available at home. The 
recommended dosage regimen for loperarnide previously used in irinotecan clinical 
trials consists of the following: 4 mg at the first onset of late diarrhea and then 2 mg 
every 2 hours until the patient is diarrhea-free for at least 12 hours. Note: This dosage 
regimen exceeds the usual dosage recommendations for loperamide. Premedication 
with loperamide is not recommended. If diarrhea occurs it is of vital importance that 
measures are taken to avoid dehydration and electrolyte imbalance. Patients should 
be supported as clinically indicated. The use of drugs with laxative properties should 
be avoided because of the potential for exacerbation of diarrhea. Patients should be 
advised to contact their Investigator to discuss any laxative use. Abdominal cramps 
should be treated the same as for diarrhea. 
Extravasation 
No severe extravasation reactions have been observed so far with CPT-11 and 
Oxaliplatin. As a general recommendation, in the event of extravasation, the following 
advice should be observed (like for any drug): 
1. stop the infusion immediately, 
2. do not remove the needle or cannula, 
3. aspirate as much infiltrated drug as possible from the subcutaneous site with the 
same needle, 
4. apply ice to the area for 15 to 20 minutes every 4 to 6 hours for the first 72 hours, 
5. watch the area closely during the following days in order to determine whether any 
further treatment is necessary. 
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Hematopoietic growth factors 
G-CSF is not recommended as primary prophylaxis, but it can be used in secondary 
prophylaxis in case of: 
- Precedent febrile neutropenia; 
- Precedent grade 4 neutropenia lasting 5 days or more; 
- More than 2 delays of the planned therapy due to neutropenia. 
Prohibited treatment 
High dose aspirin (>325 mg/day) and anticoagulants for therapeutic purpose are not 
allowed in combination with Bevacizumab. 
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9. STATISTICAL METHODS 
This is a prospective, open-label, multicentric, randomized phase III study in which 
patients, stratified according to center, ECOG PS (0 vs 1, 2), primary tumor location 
(right vs left or rectum) and previous adjuvant chemotherapy, will be randomized to 
receive one of two treatment strategies, as specified in the Paragraph “Study design”. 
9.1. Primary endpoint 
The primary endpoint is Progression Free Survival 2 (PFS2).  
PFS2 will be defined as beginning with randomization and ending with the first of the 
following events: a) death; b) disease progression on any treatment given after 1st 
progression. For patients that will not receive any treatment within 3 months after 
1st progression, PFS2 will be equal to PFS. The determination of disease progression 
will be based on investigator-reported measurements. Disease status will be 
evaluated according to RECIST 1.1 criteria. 
Censoring rules for PFS2 will be: end of study without PD, loss at follow-up. Curative 
surgery for metastasis will not result in censoring for PFS2. 
PFS2 will be analyzed both in the intention-to-treat population (primary analysis) 
and in the per-protocol population. 
9.2. Secondary endpoints 
Secondary endpoints of this study are the following: 
Progression free survival (PFS) is defined as the time from randomization to the first 
documentation of objective disease progression or death due to any cause, whichever 
occurs first. PFS will be censored on the date of the last evaluable on study tumor 
assessment documenting absence of progressive disease for patients who are alive, 
on study and progression free at the time of the analysis. Alive patients having no 
tumor assessments after baseline will have time to event censored on the date of 
randomization. 
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2nd-Progression free survival (2nd-PFS) is defined as the time from the beginning of 
the second-line treatment to the documentation of objective disease progression or 
death due to any cause, whichever occurs first. 2nd-PFS will be censored on the date 
of the last evaluable on study tumor assessment documenting absence of progressive 
disease for patients who are alive, on study and 2nd-progression free at the time of 
the analysis. 2nd-PFS will be analyzed both in the intention-to-treat population 
(whichever 2nd-line treatment will be adopted) and in the per-protocol population. 
 
Time to failure of strategy (TFS) is defined as the time time from randomization to the 
first of the following events: death; patient requires the addition of a new therapeutic 
agent (i.e. an agent not included in the original strategy); patient experiences disease 
progression while being treated with all agents that are components of the initial 
treatment strategy (except for agents which cannot be used because of persistent 
toxicity or contraindications); or patient experiences disease progression during a 
partial or complete treatment holiday from initial treatment strategy and receives no 
further therapy within 3 months. Subjects who did not have an event as stated above 
while on study will be censored at the last evaluable radiographic assessment date. 
TFS will be analyzed both in the intention-to-treat population (primary analysis) and 
in the per-protocol population. 
 
Overall survival (OS) is defined as the time from randomization to the date of death 
due to any cause. For patients still alive at the time of analysis, the OS time will be 
censored on the last date the patients were known to be alive. 
 
Objective Response Rate is defined as the percentage of patients, relative to the total 
of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to 
RECIST 1.1 criteria, during the induction and the maintenance phases of treatment. 
The determination of clinical response will be based on investigator reported 
measurements. Responses will be evaluated every 8 weeks.  
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Early Objective Response Rate is defined as the percentage of patients, relative to the 
total of the enrolled subjects, achieving a  20% decrease in the sum of diameters of 
RECIST target lesions at week 8 compared to baseline. 
 
R0 Resection Rate is defined as the percentage of patients, relative to the total of 
enrolled subjects, undergoing secondary R0 resection of metastases. Secondary R0 
surgery is defined as microscopically margin free complete surgical removal of all 
residual disease, performed during treatment or after its completion, allowed by 
tumoral shrinkage and/or disappearance of one or more lesions.  
 
Overall Toxicity Rate is defined as the percentage of patients, relative to the total of 
enrolled subjects, experiencing any adverse event, according to National Cancer 
Institute Common Toxicity Criteria (version 4.0), during the induction and the 
maintenance phases of treatment. 
 
Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled 
subjects, experiencing a specific adverse event of grade 3/4, according to National 
Cancer Institute Common Toxicity Criteria (version 4.0), during the induction and the 
maintenance phases of treatment. 
 
9.3. Study populations for primary and secondary analyses  
Intention to treat population (ITT) 
The ITT population will include all randomized patients. The ITT population will be 
the population for evaluating all primary and secondary endpoints, with the 
exception of toxicity rate and overall toxicity rate. 
 
Safety population (SP) 
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3478102 
 43 
The SP will include all patients who receive at least one dose of the study medication 
designated according to the randomization arm. The SP will be the population for 
evaluating treatment administration/compliance and safety. 
 
Per-protocol population 
The per-protocol population will include patients that proceeded according to the 
protocol, receiving at least one cycle of FOLFOX plus bev as first-line treatment and at 
least one cycle of FOLFIRI plus bev as second-line treatment (arm A) and at least one 
cycle of FOLFOXIRI plus bev as first-line treatment and at least one cycle of 5-FU +/- 
oxaliplatin +/- irinotecan plus bev as second-line treatment (arm B). 
 
9.4. Analysis of endpoints 
Analysis of primary endpoint 
The primary analysis of PFS2 will be performed in the ITT population. An unstratified 
log rank test will be used to compare PFS2 time between the two treatment arms 
with a two-sided alpha level equal to 0.0131 and 0.0455 at the interim and/or final 
analyses, respectively. Hazard ratios and 95 percent confidence intervals will be 
calculated with the use of the Cox proportional-hazards model. Survival curves will be 
calculated according to Kaplan–Meier method. A log-rank test stratified by means of 
the same factors as used for randomization will also be performed, as well as a 
multivariable model including all the baseline variables that will result significantly 
(p<0.05) related to PFS2 at the univariate analyses. 
 
Analysis of secondary endpoints 
A two-sided log-rank test will be used to compare study arms in terms of PFS, TFS 
and OS. Hazard ratios and 95 percent confidence intervals will be calculated with the 
use of the Cox proportional-hazards model. Survival curves will be calculated 
according to Kaplan– Meier methods. Log-rank tests stratified by the same factors as 
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used for randomization will also be performed, as well as multivariable models 
including all the significant baseline variables. 
Best overall response rate will be calculated as the number of patients with a CR or 
PR as best response divided by the total number of enrolled patients. The 
corresponding exact 2-sided 95% confidence interval will be calculated using a 
method based on the binomial distribution. 
R0 resection rate will be calculated as the number of patients undergoing secondary 
R0 resection of metastases divided by the total number of randomized patients in 
each arm. The corresponding exact 2-sided 95% confidence interval will be calculated 
using a method based on the binomial distribution. 
Toxicity rates and overall toxicity rate will be calculated as the number of patients 
experiencing a specific adverse event of grade 3/4 or any adverse event of grade 3/4 
divided by the total number of randomized patients and it will be summarized by the 
two arms of treatment  and also by each study medication/type of treatment and by 
periods (before first PD and after first PD). Also a separate summary of AE grade ¾ 
will be provided for patients undergoing secondary R0 resection of metastases. The 
corresponding exact 2-sided 95% confidence interval will be calculated using a 
method based on the binomial distribution. 
 
9.5. Sample size 
Based on the assumption that PFS2 of each arm follows an exponential distribution 
and the true hazard ratio (HR) for PFS2 is 0.77 between experimental group (arm B) 
vs. control group (arm A), 466 events are required for a two-sided unstratified log-
rank test with α = 0.05 to have 80% power. Assuming a proportion of PFS2 equal to 
50% at 15 months in arm A, this treatment effect can be translated to a 9% absolute 
improvement in PFS2 at 15 months in arm B. Assuming an accrual rate of 200 
subjects/year, a minimum follow up period equal to 1.5 years and an overall dropout 
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rate equal to 5%, it is estimated that the enrollment of 654 subjects, randomized in a 
1:1 ratio, is required. 
We plan a group sequential design with 1 interim analysis to assess the primary 
efficacy endpoint. The analyses will take place at 2/3 (303 events) of the primary 
events using an O’Brien Fleming alpha-spending rule. The interim analysis will assess 
superiority of experimental arm to control group for the primary endpoint because 
the study will only be considered for early termination if superiority is met. The first 
interim analysis will have a two sided alpha level of 0.0131. According to the O’Brien 
Fleming spending rule this will leave a two sided alpha level of 0.0455 for the final 
analysis. The total type I error rate will be only slightly increased. 
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10. ETHICAL ISSUES 
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study, are designed to ensure that the Sponsor and Investigator 
abide by GCP guidelines and under the guiding principles detailed in the Declaration 
of Helsinki. The study will also be carried out in keeping with applicable local law(s) 
and regulation(s). 
Documented approval from appropriate IEC(s)/IRB(s) will be obtained for all 
participating centers before start of the study, according to GCP, local laws, 
regulations and organizations. When necessary, an extension, amendment or renewal 
of the IEC/IRB approval must be obtained and also forwarded to the Sponsor. The 
responsible unit (eg, IEC/IRB, head of the study center/medical institution) must 
supply to the Sponsor, upon request, a list of the IEC/IRB members involved in the 
vote and a statement to confirm that the IEC/IRB is organized and operates according 
to GCP and applicable laws and regulations.  
Strict adherence to all specifications laid down in this protocol is required for all 
aspects of study conduct; the investigator may not modify or alter the procedures 
described in this protocol. 
Modifications to the study protocol will not be implemented by either the Sponsor or 
the investigator without agreement by both parties. However, the investigator or the 
Sponsor may implement a deviation from, or a change of, the protocol to eliminate an 
immediate hazard(s) to the study subjects without prior IEC/IRB/Sponsor 
approval/favorable opinion. As soon as possible, the implemented deviation or 
change, the reasons for it and, if appropriate, the proposed protocol amendment 
should be submitted to the IEC/IRB/head of medical institution/Sponsor. Any 
deviations from the protocol must be explained and documented by the investigator. 
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10.1. Informed Consent 
The investigator must explain to each patient (or legally authorised representative) 
the nature of the study, its purpose, the procedures involved, the expected duration, 
the potential risks and benefits involved and any discomfort it may entail. Each 
patient must be informed that participation in the study is voluntary and that he/she 
may withdraw from the study at any time and that withdrawal of consent will not 
affect her subsequent medical treatment or relationship with physician. The informed 
consent will be given by means of standard written statement, written in non-
technical language. The patient should read and consider the statement before 
signing and dating it, and should be given a copy of the signed document. If the 
subject cannot read or sign the document, oral presentation may be made or 
signature given by the subject’s legally appointed representative, if witnessed by a 
person not involved in the study, mentioning that the patient could not read or sign 
documents. No patient can enter the study before her informed consent has been 
obtained. The informed consent is part of the protocol and must be submitted by the 
investigator with to the local ethical committee. 
A copy of the patient's signed written consent will be kept by the center in the proper 
section of the Investigator Site File. 
 
10.2. Patient protection 
The names of patients will not be recorded; a sequential identification number will be 
attributed to each patient registered in the trial. This number will identify the patient 
and must be included on all electronic Case Report Forms.  
In order to avoid identification errors, patients initials (maximum of 2 letters) and 
date of birth will also be reported on the Case Report Forms. 
Investigators will guarantee that all persons involved in this study will respect the 
confidentiality of any information concerning the trial subject. 
All parties involved in this clinical trial will maintain the strict confidentiality to 
assure that neither the person nor the family privacy of the patient participating in 
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the trial is violated; appropriate measures shall be taken to avoid the access of non 
authorized persons to the trial data. The processing of the personal data of patients 
taking part in the trial, and in particular regarding data concerning consent, shall 
comply with local law on the privacy (Legge delega 127/2001) and with the 
European Directive on the Privacy of data (95/46/EC). 
The patient can withdraw consent whenever he wants and further data will not be 
collected, even if the already collected data will be used for the study’s analyses. 
10.3. Confidential subject information for samples storage  
For the storage of biological samples, specific means will be taken to ensure the 
subject’s right to privacy and the pertinent guidance documents and regulations will 
be considered. 
 
Subjects may withdraw their consent to store the biological samples. If the patient 
withdraws his consent from the study within 5 years, the biological samples will be 
destroyed. After 5 years, biological samples will be anonymized completely. At that 
time the samples cannot  be identified in any way. The samples will be maintained for 
potential analysis for 15 years from the acquisition. Samples will be destroyed 
according to GONO policies and procedures. 
 
Samples will be collected and sent to the laboratory designated for the trial where 
they will be processed. 
Tumor tissue samples, blood and plasma samples will be stored at Oncologia Medica 
2 Universitaria of Azienda Ospedaliero-Universitaria Pisana – Translational Research 
and New Technologies Department– University of Pisa, under the responsibility of Dr. 
Loupakis. 
 
To maintain privacy of information collected from samples obtained for storage and 
future analysis, GONO has developed secure policies and procedures to maintain 
subject privacy. At the clinical site, a unique Code will be placed on the blood sample 
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3478102 
 49 
for transfer to the storage facility. The Code is a random number used only to identify 
the biosample of each subject. No other personal identifiers will appear on the sample 
tube. The first Code will be replaced with a Sample Code at the Central Laboratory or 
at the GONO designated facility. This sample is now a single coded sample. The 
Sample Code is stored separately from all previous sample identifiers. A secure code, 
hereinafter referred to as a “first coding key”, will be utilized to match the Sample 
Code to the original blood code and subject number to allow clinical information 
collected during the course of the trial to be associated with the biosample. This “first 
coding key” will be transferred by the central laboratory or GONO designated facility 
under secure procedures to the GONO designated as the entrusted keyholder to 
maintain confidentiality of the biosamples. The Sample Code will be logged into the 
primary biorepository database, and in this database this identifier will not have 
identifying demographic data or identifying clinical information (i.e., race, sex, age, 
diagnosis, lab values) associated with it. The sample will be stored in a designated 
repository site with secure policies and procedures for sample storage and usage. 
 
10.4. Ethics Committe (EC) 
The Investigator must submit this protocol to the local Ethics Committee and is 
required to forward a copy of the written approval to the CRP. 
The EC approval must report, the identification of the trial (title, protocol number and 
version), the documents evaluated (protocol, informed consent material, 
advertisement when applicable) and the date of their version. 
 
10.5. Administrative responsabilities 
The Coordinating Center (U.O. Oncologia 2 Universitaria – Polo Oncologico Azienda 
Ospedaliero-Universitaria Pisana, AOUP) and the Data Center (Centro Coordinamento 
Sperimentazioni Cliniche of Istituto Toscano Tumori – Azienda Ospedaliero-
Universitaria Careggi) will be responsible for: 
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 reviewing the protocol 
 centralizing databases 
 centralizing data validation according to Data Validation Plan 
 controlling the quality of the reported data 
 emitting Data Query Forms 
 generating study program reports 
 generating the Statistical Analysis Plan 
 perform statistical analysis 
 
10.6. Trial sponsorship and financing  
 The present study is an investigator-initiated trial, carried out by participating 
clinicians, who have the intellectual ownership of the results. 
 The study is sponsored by Gruppo Oncologico Nord-Ovest (G.O.N.O.) Cooperative 
Group Via G. Mameli, 3 – Genoa (ITALY), who will provide the economical support for 
costs related to data management, statistical analysis and the other activities of 
central and group coordinating centers. 
 Roche SpA will provide vials of Bevacizumab beyond progression in both arms 
and partial financial support  for study costs.  
 No funds can be provided to ethical committees and single participating centers. 
 The study will be conducted according to the current regulations. 
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11. STUDY MONITORING 
11.1. Quality assurance 
Each participating Investigator will be responsible for ensuring data quality as 
planned in the Data Validation Plan document. Each reported information will be 
systematically checked for consistency, completeness and accuracy by the 
Coordinating Data Center that will issue Data Query Forms in case of inconsistent 
data. Local quality control will be provided by coordinating centers of each 
participating group, which  will be responsible of monitoring the centers belonging to 
their group. 
 
11.2. Responsabilities of the investigators  
The Investigators undertake to perform the study in accordance with ICH Good 
Clinical Practice and Good Clinical Practice for Trials on Medicinal Products in the 
European Community (ISBN 92 - 825-9563-3). 
The Investigator is required to ensure his compliance to the procedures required by 
the protocol with respect to the investigational drug schedule and visit schedule. The 
Investigator agrees to provide all information requested in the Case Report Form in 
an accurate and legible manner according to the instructions provided. 
The Investigator has responsibilities to the Health Authorities to take all reasonable 
steps to ensure the proper conduct of the study as regards ethics, protocol adherence, 
integrity and validity of the data recorded on the case report forms. The main duty of 
the Trial Monitor is to help the Investigator and the Coordinators to maintain a high 
level of ethical, scientific, technical and regulatory quality in all aspects of the study. 
At regular intervals during the study, the center will be contacted, through site visits, 
letters or telephone calls, to review the study progress, the investigators and subjects 
adherence to protocol requirements. 
During each monitoring visits, the following points will be scrutinized: 
 subject informed consent 
 subject recruitment and follow-up 
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 study drug allocation 
 subject compliance to the study treatment 
 study treatment accountability 
 Adverse Event documentation and reporting 
 
11.3. Source documents requirements 
According to the guidelines on ICH Good Clinical Practice, the monitor of the study 
will check the case report form entries against the source documents. These 
personnel, bound by professional secrecy, will not disclose any personal identity or 
personal medical information. 
Considering the primary end point of the study, independent review of objective 
response will be performed by an external panel. For this reason, a copy (either on CD 
or radiological film) of each CT or RMN scan performed during the study will be 
required.   
 
11.4. Use and completion of electronic case report forms (e-CRFs)  
It is the responsibility of the Investigator to prepare and maintain adequate and 
accurate e-CRFs for each patient enrolled in the study. All e-CRFs should be 
completed to ensure accurate interpretation of data. 
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12. ADVERSE EVENTS 
12.1. Definition of adverse event  
An adverse event is defined in the International Conference on Harmonisation (ICH) 
Guideline for Good Clinical Practice as “any untoward medical occurrence in a patient 
or clinical investigation subject administered a pharmaceutical product and that does 
not necessarily have a causal relationship with this treatment.” (ICH E6:1.2). See 
below (specific table), for guidelines to drug-event relationship assessment. 
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a change from 
values before the study. In general, abnormal laboratory findings without clinical 
significance (based on the investigator's judgment) should not be recorded as adverse 
events; however, laboratory value changes requiring therapy or adjustment in prior 
therapy are considered adverse events. 
Patients will be instructed by the Investigator to report the occurrence of any adverse 
event. 
 
Assessment of drug-event relationship 
Relationship Description 
unrelated There is no evidence of any causal relationship 
unlikely 
There is little evidence to suggest there is a causal 
relationship (e.g. the event did not occur within a reasonable 
time after administration of the trial medication). There is 
another reasonable explanation for the event (e.g. the 
patient’s clinical condition, other concomitant treatments). 
possible 
There is some evidence to suggest a causal relationship (e.g. 
because the event occurs within a reasonable time after 
administration of the trial medication). However, the 
influence of other factors may have contributed to the event 
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(e.g. the patient’s clinical condition, other concomitant 
treatments). 
probable 
There is evidence to suggest a causal relationship and the 
influence of other factors is unlikely.  
definitely 
There is clear evidence to suggest a causal relationship and 
other possible contributing factors can be ruled out. 
not assessable 
There is insufficient or incomplete evidence to make a clinical 
judgement of the causal relationship. 
 
12.2. Definition of Adverse Drug Reactions (ADR) 
All untoward and unintended responses to a medicinal product related to any dose 
administered. 
The phrase “responses to a medicinal product” means that a causal relationship 
between the medicinal product and the adverse event is at least a reasonable 
possibility, i.e. the relationship cannot be ruled out. 
A serious ADR (SADR) is an ADR that meets the definition of serious (provided 
below). 
 
12.3. Definition of Serious Adverse Event 
A serious adverse event (SAE) is defined as an adverse event that: 
 is fatal 
 is life threatening (places the subject at immediate risk of death): 
 requires in-patient hospitalization or prolongation of existing hospitalization 
 results in persistent or significant disability/incapacity 
 is a congenital anomaly/birth defect 
 other significant medical hazard 
A hospitalization meeting the regulatory definition for “serious” is any inpatient 
hospital admission that includes a minimum of an overnight stay in a health care 
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facility. Any adverse event that does not meet one of the definitions of serious (i.e., 
emergency room visit, outpatient surgery, or requires urgent investigation) may be 
considered by the investigator to meet the “other significant medical hazard” 
criterion for classification as a serious adverse event. Examples include allergic 
bronchospasm, convulsions, and blood dyscrasias. 
Hospitalization for the performing of protocol-required procedures or administration 
of study treatment is not classified as an SAE. 
All adverse events which do not meet any of the criteria for serious should be 
regarded as non-serious adverse events. 
All serious adverse events occurring during the study treatment period must be 
reported within 24 hours according to the procedure described below.  Any late SAE 
(occurring after this 30 days period) possibly or probably related to the study 
treatment should follow the same reporting procedure. 
Progression of colorectal cancer leading to one of the above should not be reported as 
a serious adverse event. 
 
12.4 ADVERSE EVENTS OF SPECIAL INTEREST (AESI) to bevacizumab 
Non-serious and serious  adverse events of special interest are required to be 
reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours 
after learning of the event)  Adverse events of special interest for this study include 
the following: 
 
• Hypertension ≥ grade 3 
• Proteinuria ≥ grade 3 
• GI perforation, abscesses and fistulae (any grade) 
• Wound healing complications ≥ grade 3 
• Haemorrhage ≥ grade 3 (any grade CNS bleeding; ≥ grade 2 haemoptysis) 
• Arterial thromboembolic events (any grade) 
• Venous thromboembolic events ≥ grade 3 
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• PRES (or RPLS; any grade) 
• CHF ≥ grade 3 
• Non-GI fistula or abscess ≥ grade 2 
 
Other Non-Serious or Serious AESIs for this study include the following: 
a. Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s 
law. The finding of an elevated ALT or AST ( 3  baseline value) in combination with 
either an elevated total bilirubin ( 2  ULN) or clinical jaundice in the absence of 
cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of 
severe liver injury. Therefore, investigators must report as an adverse event the 
occurrence of either of the following: 
- treatment-emergent ALT or AST  3  baseline value in combination with total 
bilirubin  2  ULN (of which ≥ 35% is direct bilirubin); 
- treatment-emergent ALT or AST  3  baseline value in combination with clinical 
jaundice. 
The most appropriate diagnosis or, (if a diagnosis cannot be established) the 
abnormal laboratory values, should be recorded on the Adverse Event eCRF page and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event), either as a serious adverse event or a non-serious adverse event of special 
interest. 
 
b. Suspected transmission of an infectious agent by the study drug, as defined below: 
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an infection in 
a patient exposed to a medicinal product. This term applies only when a 
contamination of the study drug is suspected. 
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Regardless of relationship or severity, these events will be recorded if they start from 
the time of the first dose (including partial dose) of study treatment until 6 months 
after the last study treatment. AESIs will be followed until resolution. All these AESIs 
must be reported to the Sponsor immediately (i.e. no more than 24 hours after 
learning of the event). 
 
12.5. Deaths reporting procedure 
Any death occurring between the randomization and 30 days following the treatment 
must be reported to the Sponsor within 24 hours, regardless of the relation to study 
drug(s). Deaths occurring later than 30 days after the treatment should be reported 
on the death report form section of the e-CRF regardless of cause. 
 
12.6. Pregnancies reporting procedure 
The investigator must report to the sponsor any pregnancy occurring in a study 
subject, or in his partner, during the subject’s participation in this study. The report 
should be submitted within the same timelines as an SAE, although a pregnancy per 
se is not considered an SAE. 
For a study subject, the outcome of the pregnancy should be followed up carefully, 
and any abnormal outcome of the mother or the child should be reported. 
For the pregnancy of a study subject’s partner, all efforts should be made to obtain 
similar information on course and outcome, subject to the partner’s consent. 
 
12.7. Reporting procedure 
a. Reporting Procedures for All Adverse Events 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by subjects are properly captured in the subjects’ medical 
records. 
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The following adverse event attributes must be assigned by the investigator: adverse 
event diagnosis or syndrome(s) (if known, signs or symptoms if not known); event 
description (with detail appropriate to the event); dates of onset and resolution; 
severity; outcome, assessment of relatedness to study treatment; and action taken.  
Medically significant adverse events considered related to the treatment by the 
investigator or the sponsor will be followed until resolved or considered stable.  
It will be left to the investigator’s clinical judgment to determine whether an adverse 
event is related and of sufficient severity to require the subject’s removal from 
treatment or from the study. A subject may also voluntarily withdraw from treatment 
due to what he or she perceives as an intolerable adverse event. If either of these 
situations arises, the subject should be strongly encouraged to undergo an end-of-
study assessment and be under medical supervision until symptoms cease or the 
condition becomes stable. 
 
b. Serious Adverse Events Reporting Procedures  
Serious adverse events will be collected and recorded throughout the study period, 
defined as  through to 6 months after the last dose of the treatment or the end of the 
study (including the follow-up period), whichever is longer. 
The investigator should notify the Sponsor of all serious adverse events occurring at 
the site(s) in accordance with local procedures, statutes and the European Clinical 
Trial Directive (where applicable). The Sponsor will medically review all SAEs. 
The Sponsor will ensure the notification of the appropriate Ethics Committees, 
Competent Authorities and participating Investigators of all serious adverse events 
occurring at the site(s) in accordance with local legal requirements, statutes and the 
European Clinical Trial Directive.  
 
12.8. Follow-up 
Patients withdrawn from the study treatment due to any adverse event will be 
followed at least until the outcome is determined, even if it implies that the follow-up 
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continues after the patients has left the trial, and where appropriate until the end of 
the planned period of follow-up. 
In case of serious adverse event, the patient must be followed until clinical recovery is 
complete and laboratory results have returned to normal, or until symptoms have 
stabilized. This may imply that the follow-up will continue after the patient has left 
the trial. 
Further information will be noted on the SAE form, by ticking the box marked 
“follow-up” and will be sent to the Coordinating Center as information becomes 
available. 
 
12.9 Post-study follow up  
After study drug treatment ends, anti-cancer medications taken by the patient should 
be documented in the eCRF. 
Patients will be evaluated approximately every month to determine their survival 
status. Telephone follow-up is acceptable. Site staff must use caution when contacting 
the patient’s family for this information, especially if they are no longer under the 
care of the investigator, so as to not inadvertently cause any distress to the family of a 
patient who is no longer alive. 
During this period, If the investigator becomes aware of a serious adverse event with 
a suspected causal relationship to the investigational medicinal product that occurs 
after the end of the clinical trial, the investigator shall, without undue delay, report 
the serious adverse event to the Sponsor.  
The investigator should report these events directly to the Sponsor, by completing 
the Serious Adverse Event / Adverse Event of Special Interest Reporting Form that 
will be sent to the Coordinating Center. 
Subjects who withdraw consent from study drug treatment should enter the post-
study follow-up period (unless consent to follow-up is specifically withdrawn). 
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Details should be documented on the specified Serious Adverse Event Form.  
 
Please fax the report to 050.992069 
and mail a .pdf scan version to: 
tribe2study@gmail.com 
 
The Sponsor will also send the report to national authorities, Ethic Committees (EC) 
and investigators as appropriate, according to local regulations. 
 
In addition, the Sponsor shall supply Roche with a copy of all above mentioned safety report 
regardless of the causality assessment concerning the Pharmaceutical Product 
administration. 
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 The association of chemotherapy and bevacizumab (bev) is a standard option for the 
first-line treatment of unresectable metastatic colorectal cancer patients. In particular, 
an oxaliplatin-based doublet plus Bev is a widely used regimen in this setting. 
 
 Recent results from phase III TRIBE trial demonstrated that the triplet FOLFOXIRI plus 
bev, compared to first-line FOLFIRI plus bev, provides a significant advantage in terms 
of PFS and RR and a benefit in terms of OS with a trend towards significance. At the 
same time, phase II OLIVIA trial showed that FOLFOXIRI plus bev allows to achieve an 
higher R0 resection rate, with encouraging results in terms of PFS, in the setting of 
unresectable mCRC patients with liver-limited disease. 
 
 A sustained inhibition of angiogenesis across different lines of treatment is an 
efficacious strategy in the management of mCRC. As demonstrated by both ML18147 
and BEBYP trials, the prosecution of bev beyond the clinical evidence of disease 
progression provides a survival benefit. 
 
 The optimal duration of chemotherapy plus bev is highly debated. Phase III OPTIMOX1, 
2, COIN, CONcePT and GISCAD trials address this issue, substantially evidencing that 
the choice not to continuously administer the treatment until the evidence of disease 
progression, but to alternate periods of less intensive chemotherapy or chemo-holidays 
can be pursued without compromising patients’ prognosis. 
 
 Both phase III randomized SAKK 41/06 and CAIRO-3 trials addressed the issue of 
maintenance with bev. SAKK 41/06 did not demonstrate the non-inferiority of 
interrupting instead of prosecuting bev until the time of progression. CAIRO-3 trial met 
its primary endpoint PFS2 evidencing an advantage by the prosecution of Capecitabine 
plus Bev until disease progression, compared to observation. 
 
 The opportunity to alternate induction periods, able to rapidly induce a relevant tumor 
shrinkage, and maintenance phases in the disease history of mCRC patients could be  
considered a valuable strategy. 
 
On the basis of these considerations, a first-line doublet plus bev followed by a second-
line switched doublet (from oxaliplatin to irinotecan and viceversa) plus bev is a 
standard option for mCRC patients. Only retrospectively collected data are currently 
available about the efficacy of first-line FOLFOXIRI plus bev followed by second-line 
rechallenge with FOLFOXIRI plus bev. We therefore designed the present phase III 
randomized trial of first-line FOLFOXIRI plus bev followed by reintroduction of 
FOLFOXIRI plus bev at progression versus FOLFOX plus bev followed by FOLFIRI plus 
bev at progression in first- and second-line treatment of unresectable mCRC patients. 
  




To compare the two proposed strategies in terms of Progression Free Survival 2 (PFS2) 
Secondary objectives 
To  compare the two proposed strategies in terms of  :  
 1st-line Progression-free survival (PFS) 
 2nd-line Progression-free survival (2nd-PFS)  
 Time to failure of strategy (TFS) 
 Overall Survival (OS) 
 Response rate in 1st and 2nd-line  
 Early Objective Response 
 R0 Resection Rate 
 Safety profile 
 Translational analyses. 
Definition of primary endpoint 
PFS2 will be defined as beginning with randomization and ending with the first of the 
following events: a) death; b) disease progression on any treatment given after 1st 
progression. For patients that will not receive any treatment within 3 months after 1st 
progression, PFS2 will be equal to PFS. Censoring rules for PFS2 will be: end of study 
without PD, loss at follow-up. Curative surgery for metastases will not result in 
censoring for PFS2 
 
Definition of secondary endpoints 
PFS is defined as the time from randomization to the first documentation of objective 
disease progression or death due to any cause, whichever occurs first. The 
determination of disease progression will be based on investigator-reported 
measurements. Disease status will be evaluated according to RECIST 1.1 criteria. 
 
2nd PFS is defined as the time from the beginning of the second-line treatment to the 
documentation of objective disease progression or death due to any cause, whichever 
occurs first. The determination of disease progression will be based on investigator-
reported measurements. Disease status will be evaluated according to RECIST 1.1 
criteria. 2nd-PFS will be analyzed both in the intention-to-treat population (whichever 
2nd-line treatment will be adopted) and in the per-protocol population. 
TFS is defined as the time from randomization to the first of the following events: 
death; patient requires the addition of a new therapeutic agent (i.e. an agent not 
included in the original strategy); patient experiences disease progression while being 
treated with all agents that are components of the initial treatment strategy (except for 
agents which cannot be used because of persistent toxicity or contraindications); or 
patient experiences disease progression during a partial or complete treatment holiday 
from initial treatment strategy and receives no further therapy within 3 months. 
Subjects who did not have an event as stated above while on study will be censored at 
the last evaluable radiographic assessment date.  
OS is defined as the time from randomization to the date of death due to any cause. 
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Objective response rate is defined as the percentage of patients, relative to the total of 
enrolled subjects, achieving a complete (CR) or partial (PR) response, according to 
RECIST 1.1 criteria. 
R0 resection rate is defined as the percentage of patients, relative to the total of enrolled 
subjects, undergoing secondary R0 resection of metastases. 
Overall toxicity rate is defined as the percentage of patients, relative to the total of 
enrolled subjects, experiencing any adverse event, according to National Cancer 
Institute Common Toxicity Criteria (version 4.0), during the induction and the 
maintenance phases of treatment. 
Statistical considerations 
Based on the assumption that PFS2 of each arm follows an exponential distribution and 
the true hazard ratio (HR) for PFS2 is 0.77 between experimental group (arm B) vs. 
control group (arm A), 466 events are required for a two-sided unstratified log-rank 
test with α = 0.05 to have 80% power. 
Assuming a proportion of PFS2 equal to 50% at 15 months in arm A, this treatment 
effect can be translated to a 9% absolute improvement in PFS2 at 15 months in arm B. 
Assuming an accrual rate of 200 subjects/year, a minimum follow up period equal to 
1.5 years and an overall dropout rate equal to 5%, it is estimated that the enrollment of 
654 subjects, randomized in a 1:1 ratio, is required. 
The primary analyses of PFS2 will be performed in the ITT population. An unstratified 
log rank test will be used to compare PFS2 time between the two treatment arms with a 
two alpha level equal to 0.0131 and 0.0455 at the interim and/or final analyses, 
respectively. 
We plan a group sequential design with 1 interim analysis to assess the primary 
efficacy endpoint. The analyses will take place at 2/3 (303 events) of the primary 
events using an O’Brien Fleming alpha-spending rule. The interim analysis will assess 
superiority of experimental arm to control group for the primary endpoint because the 
study will only be considered for early termination if superiority is met. The first 
interim analysis will have a two sided alpha level of 0.0131. According to the O’Brien 
Fleming spending rule this will leave a two sided alpha level of 0.0455 for the final 
analysis. The total type I error rate will be only slightly increased. 
  




 Histologically proven diagnosis of colorectal cancer 
 Initially unresectable metastatic colorectal cancer not previously treated with 
 chemotherapy for metastatic disease 
 At least one measurable lesion according to RECIST1.1 criteria 
 Availability of a tumoral sample 
 Male or female of 18-75 years of age 
 ECOG PS < or = 2 if aged < 71 years, ECOG PS = 0 if aged 71-75 years 
 Life expectancy of at least 12 weeks 
 Previous adjuvant chemotherapy allowed only if with fluoropyrimidine 
monotherapy  and more than 6 months elapsed between the end of adjuvant and 
first relapse 
 Neutrophils >1.5 x 109/L, Platelets >100 x 109/L, Hgb >9 g/dl 
 Total bilirubin 1.5 time the upper-normal limits (UNL) of the normal values and 
ASAT  (SGOT) and/or ALAT (SGPT) <2.5 x UNL (or <5 x UNL in case of liver 
metastases)  alkaline phosphatase <2.5 x UNL (or <5 x UNL in case of liver 
metastases) 
 Creatinine clearance >50 mL/min or serum creatinine 1.5 x UNL 
 Urine dipstick of proteinuria <2+. Patients discovered to have 2+ proteinuria on 
dipstick  urinalysis at baseline, should undergo a 24-hour urine collection and must 
demonstrate  <1 g of protein/24 hr 
 Women of childbearing potential must have a negative blood pregnancy test at the 
baseline visit. For this trial, women of childbearing potential are defined as all women 
after puberty, unless they are postmenopausal for at least 12 months, are surgically 
sterile, or are sexually inactive. 
 Subjects and their partners must be willing to avoid pregnancy during the trial and 
until 6 months after the last trial treatment. Male subjects with female partners of 
childbearing  potential and female subjects of childbearing potential must, therefore, be 
willing to use adequate contraception as approved by the investigator (barriere 
contraceptive measure or oral contraception) 
 Will and ability to comply with the protocol 
 Written informed consent to study procedures and to molecular analyses 
  




 Radiotherapy to any site within 4 weeks before the study 
 Previous adjuvant oxaliplatin-containing chemotherapy  
 Previous treatment with bevacizumab  
 Untreated brain metastases or spinal cord compression or primary brain tumours 
 History or evidence upon physical examination of CNS disease unless adequately 
treated 
 Symptomatic peripheral neuropathy > 2 grade NCIC-CTG criteria 
 Serious, non-healing wound, ulcer, or bone fracture 
 Evidence of bleeding diathesis or coagulopathy 
 Uncontrolled hypertension and prior histor of hypertensive crisis or hypertensive 
 encephalopathy 
 Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular 
 accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New 
York  Heart Association (NYHA) grade II or greater congestive heart failure, 
serious cardiac  arrhythmia requiring medication 
 Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent 
 arterial thrombosis) within 6 months of study enrolment 
 Any previous venous thromboembolism > NCI CTCAE Grade 3 
 History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI 
 bleeding within 6 months prior to the first study treatment. 
 Current or recent (within 10 days prior to study treatment start) ongoing treatment 
with  anticoagulants for therapeutic purposes 
 Chronic, daily treatment with high-dose aspirin (>325 mg/day) 
 Treatment with any investigational drug within 30 days prior to enrollment or 2 
 investigational agent half-lives (whichever is longer) 
 Other co-existing malignancies or malignancies diagnosed within the last 5 years 
with  the exception of localized basal and squamous cell carcinoma or cervical 
cancer in situ 
 Major surgical procedure, open biopsy, or significant traumatic injury within 28 
days  prior to study treatment start, or anticipation of the need for major surgical 
procedure  during the course of the study 
 Lack of physical integrity of the upper gastrointestinal tract, malabsorption 
syndrome, or  inability to take oral medication 
 Pregnant or lactating women. Women of childbearing potential with either a 
positive or no pregnancy test at baseline. Sexually active males and females (of 
childbearing potential) unwilling to practice contraception during the study (barriere 
contraceptive measure or oral contraception). 
  




Arm A - mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 
cycles)  
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluoruracil 400 mg/sqm iv bolus, day 1 
 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1 
If no progression occurs, patients will receive maintenance 5-FU/LV plus bev at the 
same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be 
repeated biweekly until disease progression, unacceptable toxicity or patient’s refusal. 
The prosecution of bev until disease progression is recommended also in the case of 
interruption of 5-fluoruracil because of adverse events, patient’s refusal or 
investigator’s choice. At the time of disease progression patients will receive FOLFIRI 
plus bev* (to be repeated every 2 weeks for a maximum of 8 cycles): 
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Irinotecan 180 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluoruracil 400 mg/sqm iv bolus, day 1 
 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1 
*Doses may be modified according to patient’s tolerance to 1st-line regimen. 
If no progression occurs, patients will receive maintenance 5-FU/LV plus bev at the 
same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be 
repeated biweekly until disease progression, unacceptable toxicity or patient’s refusal. 
The prosecution of bev until disease progression is recommended also in the case of 
interruption of 5-fluoruracil because of adverse events, patient’s refusal or 
investigator’s choice. 
 
Arm B - FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 
cycles): 
 Bevacizumab 5 mg/kg iv over 30 minutes, day 1 
 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 
 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 
 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 
 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 
If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 
5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-
FU/LV plus bev will be repeated biweekly until disease progression, unacceptable 
toxicity or patient’s refusal. The prosecution of bev until disease progression is 
recommended also if 5-fluorouracil is interrupted because of adverse events, patient’s 
refusal or investigator’s choice. At the time of disease progression, patients will re-
introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for 
a maximum of 8 cycles. If  persistent neurotoxicity ≥G2, FOLFIRI plus bev will 
administered for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI 
plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in 
the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly 
until disease progression, unacceptable toxicity or patient’s refusal. The prosecution of 
bev until disease progression is recommended also in the case of interruption of 5-
fluorouracil because of adverse events, patient’s refusal or investigator’s choice.  
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1. Until the 2nd evidence of disease progression 
2. Blood count and differential, bilirubin (total and direct), AST, ALT, alkaline phosphatase, 
albumin, LDH, serum creatinine, glucose, electrolytes (sodium, potassium, calcium), International 
normalized ratio (INR)/Activated partial Thromboplastin Time (APTT), CEA, CA19.9; pregnancy 
test (if clinically indicate); 
3. Blood count and differential, bilirubin (total and direct), serum creatinine, INR/APTT (only for 
patients on anticoagulation therapy); 
4. Only a the first and second evidence of PD 
5. AE assessment to be started after signing of IC until 30 days after last study treatment 





















































































Informed Consent X     
Complete medical history X     
Inclusion/Exclusion Criteria Checked X     
Tumor assessment (total-body CT or 
abdomen MRI + chest CT) 
X   X  
Collection of a CD-ROM copy of CT 
scan 
X   X  
12-lead ECG X     
ECOG PS X X X X  
Physical examination X  X X  
Complete blood examination2 X   X  
Partial blood examination3  X X   
Dipstick proteinuria X X X   
Collection of a paraffin-embedded 
tissue sample X 
    
Collection of blood samples   X  X
4  
Adverse events and toxicity   X
5  X6 
Survival follow up     X 
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Dose reductions and delays for chemotherapeutic agents 
 
TOXICITY AT THE START OF 




Irinotecan Oxaliplatin 5FU 
WBC < 3.000/mm3 
Hold until resolution 
Neutrophils < 1.000/mm3 
Platelets < 100.000/mm3 
Diarrhea > 1 
Mucositis > 1 
Any other non-hematological toxicity > 2 
Hand/foot syndrome 3-4 100% 100% STOP 
Neurotoxicity > 3 100% STOP 100% 
 
PREVIOUS TOXICITY GRADE Irinotecan Oxaliplatin 5FU 
Neutropenia >5 days 4 
75% 75% 100% Febrile Neutropenia 4 
Thrombocytopenia 3-4 
Diarrhea 3 75% 100% 75% 
Diarrhea 4 50% 100% 50% 
Stomatitis 3 100% 100% 75% 
Stomatitis 4 100% 100% 50% 
Myocardial Ischemia NA 100% 100% STOP 
 
  
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3478102 
 74 
 
Dose reductions and delays for bevacizumab 
 
Event Grade Adjustment to bev 
Hypertension 
3 
If not controlled by 3-drug medication, 
permanently discontinue 




Any grade CNS Permanently discontinue 
≥2  
(pulmonary) 





3 Hold temporarily 
4 Permanently discontinue 
Arterial 
thrombosis 
Any Grade Permanently discontinue 
Congestive Heart 
Failure 




- For 2+ dipstick: may administer bev, obtain 24-
hour urine sample prior to next bev dose 
Suspend bev for ≥2 g /24 hours and resume when 
proteinuria is <2 g /24 hours and protein 
creatinine ratio <2.0 
- For 3+ dipstick: obtain 24 hour urine sample 
prior to bev administration 
Suspend bev for ≥2 g /24 hours and resume when 
proteinuria is <2 g /24 hours and protein 
creatinine ratio <2.0 
4 Permanently discontinue  
GI perforation Any grade Permanently discontinue  
 PRES/RPLS Any grade Permanently discontinue 
Fistula 
Any grade TE fistula Permanently discontinue  








3 Hold until recovery to ≤ Grade 1  
4 Permanently discontinue 
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Total number of centers 
About 60 Italian Oncology Units 
Study length 
Study length is planned to be about 4.5 years since the enrollment is expected to be 
about 3 years, with a minimum period of follow-up of 18 months 
Enrollment and data management 
Registration, randomization and data collection are centralized at Ufficio 
Sperimentazioni Cliniche - Unit of Oncology, Azienda Ospedaliero-Universitaria Pisana 
and Clinical Trials Coordinating Center Istituto Toscano Tumori
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14.2. RECIST 1.1 
Response and progression will be evaluated in this study using the RECIST criteria 
version 1.1. Changes in only the largest diameter (unidimensional measurement) of the 
tumor lesions are used. 
Measurable Disease 
Tumor lesions: Measurable lesions are defined as those that can be accurately measured 
in at least one dimension (longest diameter to be recorded) with a minimum size of 
• 10 mm by CT scan (CT scan slice thickness no greater than 5 mm) or MRI. If scans 
with slice thicknesses greater than 5mm are used, the minimum size should be twice 
the slice thickness.  
• 20 mm by chest x-ray  
• 10 mm caliper measurement by clinical examination (lesions which cannot be 
accurately   measured with calipers should be recorded as non-measurable    
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only 
the short axis will be measured and followed.    
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components 
that can be evaluated by CT or MRI, can be considered as measurable lesions if the soft 
tissue component meets the definition of measurability.   All tumor measurements must 
be recorded in millimetres (or decimal fractions of centimetres). Tumor lesions situated 
in a previously irradiated area are not considered measurable unless there has been 
demonstrated progression in the lesion.    
Non-Measurable Disease: All other lesions (or sites of disease), including small lesions 
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(longest diameter <10 mm or pathological lymph nodes with ≥10 to < 15mm short axis) 
are considered non-measurable disease. Leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitic involvement of skin or lung, inflammatory 
breast disease, abdominal masses/ abdominal organomegaly identified by physical 
examination that is not measurable by reproducible imaging techniques and blastic bone 
lesions are all non-measurable.  
Target Lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs should be identified as target 
lesions and be recorded and measured at baseline. These 5 lesions should be selected on 
the basis of their size (lesions with the longest diameter), be representative of all 
involved organs and should be suitable for reproducible repeated measurements. A sum 
of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. The baseline sum 
diameters will be used as reference to further characterize any objective tumor 
regression of the measurable dimension of the disease. If there are >5 measurable 
lesions, those not selected as target lesions will be considered together with non- 
measurable disease as non-target lesions. 
Non-target Lesions: All non-measurable lesions (or sites of disease) plus any 
measurable lesions over and above the 5 listed as target lesions. Measurements are not 
required but these lesions should be noted at baseline and should be followed as 
“present”, “absent” or in rare cases “unequivocal progression”. 
Best Response: All subjects will have their BEST RESPONSE on study classified as 
outlined below: 
Complete Response (CR): Disappearance of all clinical and radiological evidence of 
tumor (both target and non-target). Any pathological lymph nodes (whether target or 
non target) must have a reduction in short axis to < 10mm. 
Partial Response (PR): At least a 30% decrease in the sum of diameters of target 
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lesions taking as reference the baseline sum, no unequivocal progression of existing non 
target lesions and no appearance of new lesions. 
Stable Disease (SD): Steady state of disease. Neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non 
target lesions and no appearance of new lesions. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target 
lesions taking as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5mm. Unequivocal progression of 
existing non target lesions or the appearance of one or more new lesions will also 
constitute progressive disease. 








CR CR No CR 
CR Non-CR/Non-PD No PR 








Non-PD or not all 
evaluated 
No SD 
PD Any Yes or No PD 
Any Any Yes PD 
Any PD Yes or No PD 
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Table 2: Response for patients with Non-Target Lesions only 




















* Non-CR/non-PD is preferred over “stable disease” for non-target disease. 
 
Methods of Measurement - The same method of assessment and the same technique 
should be used to characterize each identified and reported lesion at baseline and 
during follow-up. 
Clinical Lesions - Clinical lesions will only be considered measurable when they are 
superficial (e.g. skin nodules, palpable lymph nodes) and ≥ 10mm diameter as assessed 
using calipers. For the case of skin lesions, documentation by colour photography 
including a ruler to estimate the size of the lesion is recommended. 
Chest X-ray - Lesions on chest X-ray are acceptable as measurable lesions when they 
are clearly defined and surrounded by aerated lung. However, chest CT is preferable. 
CT / MRI - CT is the best currently available and reproducible methods to measure 
target lesions selected for response assessment. CT scans should be performed with cuts 
of 5 mm or less in slice thickness. When CT scans have slice thickness greater than 5 
mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI 
is also acceptable. This applies to the chest, abdomen and pelvis. Head & neck and 
extremities usually require specific protocols. 
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Ultrasound - Ultrasound is not useful in assessment of lesion size and should not be 
used as method of measurement. If new lesions are identified by ultrasound in the 
course of the study, confirmation by CT or MRI is advised. 
Endoscopy / Laparoscopy - The utilization of these techniques for objective tumor 
evaluation is not advised. 
Cytology / Histology - These techniques can be used to differentiate between PR and 
CR in rare cases (for example, residual lesions in tumor types such as germ cell tumors, 
where known residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or 
stable disease is mandatory to differentiate between response or stable disease (an 
effusion may be a side effect of the treatment) and progressive disease. 
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14.3. NCI Common Terminology Criteria for Adverse Events 
This study will utilize the NCI Common Terminology Criteria for Adverse Events Version 
4.0 for toxicity and serious adverse event reporting. A copy of the CTC Version 4.0 can be 
downloaded from the CTEP home page: 
http/ctep.cancer.gov:protocolDevelopment:electronic_applications:ctc.htm - ctc_40)  
All appropriate treatment areas should have access to a copy of the CTC Version 4.0. 
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14.4 SAE report form 
 
Please send completed form to tribe2study@gmail.com 
 
    
 





SPONSOR USE ONLY 
Receipt date of this report 
(stamp or date) 
 
TYPE OF REPORT 
  Initial   Follow-up 
A. REPORTER INFORMATION 
Reporter’s First Name Reporter’s Last Name 
            
Investigator’s First Name (if different from Reporter) Investigator’s Last Name (if different from Reporter) 
 
            
Address City  
            
Country Phone Number 
            
E-Mail: Fax Number 
            
B. SUBJECT INFORMATION 
Subject ID 
 
        /       /        
Study name Center name. Patient code  
Subject Initials Sex Height Weight 
        Female     Male           cm           kg 
Date of Birth  (dd/mmm/yyyy)   OR Age at Time of Adverse Event (Specify unit, e.g. years months, etc.) 
     /     /            
Ethnicity/Race      American Indian/Alaska native    Asian    Black or African American    Caucasian/White    Hispanic or Latino 
    Native Hawaiian or other Pacific islander     other _____________________________________________________ 













          /    /         /    /      
          /    /         /    /      
          /    /         /    /      
          /    /         /    /      
          /    /         /    /      
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D. CONCOMITANT MEDICATIONS 
Drug Trade Name Single Dose 
Frequency of 
Administration 





                            /    /         /    /           
                            /    /         /    /           
                            /    /         /    /           
                            /    /         /    /           
                            /    /         /    /           
 
E. INVESTIGATIONAL MEDICINAL PRODUCT(S) 
Indication of Investigational Medicinal Product(s) 
      
 
1 
Investigational Medicinal Product Name / Route of Administration: 
 
      
Not yet administered:         
Date of first administration:  
 







Date of most recent administration prior to SAE: 
 








Number of cycles prior to SAE: 
 
 
ACTIONS TAKEN REGARDING THIS INVESTIGATIONAL MEDICINAL PRODUCT 
 Temporary discontinued on:      /     /      . . . . . . . . . .  Event subsided? . . . . . . . . . . . . . . .   Yes  No  Unknown 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  If “yes”, how long after cessation of treatment?        
 
 If temporary discontinued, restarted on:      /     /      . At previous dose? . . . . . . . . . . . . . .   Yes  No  Unknown 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Event subsequently reappeared?   Yes  No  Unknown 
Permanently discontinued on:      /     /      . . . . . . . . . .      
 Dose Reduced on:      /     /      . . . . . . . . . . . . . . . . . . .  Event subsided? . . . . . . . . . . . . . . .   Yes  No  Unknown 
 Treatment Continued without Change 
 Not Applicable 
 Unknown 
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2 
Investigational Medicinal Product Name / Route of Administration 
 
      
Not yet administered:         
Date of first administration:  
 
(dd/mmm/yyyy)          /    /     
 







Date of most recent administration prior to SAE: 
 
(dd/mmm/yyyy)          /    /     
 









Number of cycles prior to SAE: 
 
 
ACTIONS TAKEN REGARDING THIS INVESTIGATIONAL MEDICINAL PRODUCT 
 Temporary discontinued on:      /     /      . . . . . . . .  .  Event subsided? . . . . . . . . . . . . . . .   Yes  No  Unknown 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  If “yes”, how long after cessation of treatment?        
 
 If temporary discontinued, restarted on:      /     /       At previous dose? . . . . . . . . . . . . . .   Yes  No  Unknown 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Event subsequently reappeared?   Yes  No  Unknown 
Permanently discontinued on:      /     /      . . . . . . . . . .      
 Dose Reduced on:      /     /      . . . . . . . . . . . . . . . . . . .  Event subsided? . . . . . . . . . . . . . . .   Yes  No  Unknown 
 Treatment Continued without Change 
 Not Applicable 
 Unknown 
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F. ADVERSE EVENT(S) (If there are more than three adverse events, reprint this page as many times as is necessary.) 
Report adverse event diagnosis 
(ses), if not available provide sign(s) 
and symptom(s) 
AE      :       AE      :       AE      :       
Onset Date and Time (dd/mmm/yyyy  
hh:mm) 
     /     /         :        /     /         :        /     /         :   
Resolution Date (dd/mmm/yyyy)      /     /           /     /           /     /      
Duration, if less than 24h         hr   min         hr   min         hr   min 
SEVERITY    
Severity Grade 
Use either NCI-CTC grading OR 
Qualitative Scale 
  1  Mild   1  Mild   1  Mild 
  2  Moderate   2  Moderate   2  Moderate 
  3  Severe   3  Severe   3  Severe 
  4  Life-threatening   4  Life-threatening   4  Life-threatening 
   5   Death   5    Death   5       Death 
SERIOUSNESS    
Resulted in Death    
Is Life-Threatening    
Requires/Prolongs Hospitalization     
Persistent/Significant 
Disability/Incapacity    
Medically Significant    
Is Congenital Anomaly/Birth Defect 
Parent-Child/Foetus Report Form 
must be completed 
Parent-Child/Foetus Report Form 
must be completed 
Parent-Child/Foetus Report Form 
must be completed 
OUTCOME 
Unknown (only applicable if subject 
is lost to follow-up) 
   
Fatal (AE resulted in death)    
Ongoing    
Resolved without Sequelae    
Resolved with Sequelae 
   
Specify:  Specify:  Specify:  
 
                  
 
RELATION TO THE INVESTIGATIONAL MEDICINAL PRODUCT(S) / STUDY TREATMENT If an event is unrelated, please 
indicate any other causality factors in the appropriate section and/or provide further details in the narrative (Description of Adverse Event(s)). 
 Related Unrelated Related Unrelated Related Unrelated 
Investigational Medicinal Product 1       
Investigational Medicinal Product 2       
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G. DESCRIPTION OF ADVERSE EVENT(S) 
Provide a detailed description of AE, i.e. clinical course of event(s), signs, symptoms, laboratory results, treatment of AE, etc. 

























1) In Case of Death 
 Cause of Death:   AE     Other If “other”, specify:        
  
 Date of Death:      /     /      Autopsy performed?   Yes    No If “yes”, please attach autopsy report if available. 
2) In Case of Hospitalization or Prolonged Hospitalization 
 Admission Date:      /     /      Discharge Date:      /     /       Not Discharged 
H. RELEVANT TESTS/PROCEDURES/LABORATORY TESTS TO CONFIRM ADVERSE EVENT 
 













I. OTHER RELEVANT RISK FACTORS 
  Alcohol Use   Physical Therapy   Contraceptive   Smoking 
  Pace Maker   Drug Dependence   Radiation Therapy   Diet 
  Metabolic Disorders   Drug Abuse   Obesity   Allergy 
  Implants   Other, specify: __________________________________________________________________________ 
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J. CAUSALITY FACTORS OTHER THAN TRIAL TREATMENT 
  
  Concomitant Medication, please specify suspected drug:__________________________________________________(record details in section D) 
 
  Medical History, please specify disease:_______________________________________________________________(record details in section C) 
 
  Disease Under Study                 Disease Progression; specify:_________________________________________________________________ 
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